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ABSTRACT
Wei Liu, PhD. The University of Memphis. November 2017. Long-term Neurocognitive,
Behavior and Emotional Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia
Treated with Chemotherapy Only. Major Professor: Vikki Nolan.
Contemporary chemotherapy results in a greater than 90% five-year survival rate from
childhood acute lymphoblastic leukemia (ALL). However, long-term survivors of childhood
ALL still present with a higher prevalence of neurocognitive function problems, specifically
executive function deficits, and behavior emotional problems compared to the general
population. We conducted two epidemiologic studies of these issues and a Phase II clinical trial
to improve executive deficits among long-term childhood ALL survivors.
First, we evaluated the association between sustained attention and parent-rated
behavioral inattention at the end of chemotherapy, and neurocognitive outcomes at long-term
follow-up (LTFU). Patients demonstrated higher frequency of impairment in sustained attention
(range 38 - 56%) and behavior inattention (20%) at the end of therapy, and executive function
deficits (range 21-54%) at LTFU, compared to national norms. Survivors improved on measures
of sustained attention at LTFU. Chemotherapy exposure predicted outcomes at both time points,
which suggests early therapeutic interventions on neurocognitive function.
Next, we examined the prevalence and pattern of parent- and self-reported child
behavioral and emotional symptoms and mental health disorders at LTFU, and the impact of
parent self-reported emotional distress and post-traumatic stress symptoms (PTSS) on the report
of child’s outcome. Symptoms reported were consistent between child and parent on inattention
(28% and 24%), and Oppositional Defiant Disorder (20% and16%). A high proportion of anxiety
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disorders reported by parents were significantly associated with parent self-reported emotional
distress and PTSS rather than with survivors’ self-report of anxiety symptoms, which suggests
that emotional distress in parents should be taken into consideration for preventative intervention
targeting behavioral outcomes in survivors of childhood ALL.
In the final study, we designed and conducted a Phase II trial combining Transcranial
Direct Current Stimulation (tDCS) and cognitive training to evaluate feasibility and potential
efficacy of tDCS on improving executive function. Participants were adult survivors of ALL
with executive function deficits. After 5-weeks of self-administered remote sessions, tDCS
showed marginal clinically meaningful effect sizes with low adverse event rate. These findings
suggest a larger randomized clinical trial tDCS may be warranted.
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Chapter 1
INTRODUCTION
Part 1: Childhood Acute Lymphoblastic Leukemia (ALL)
Childhood acute lymphoblastic leukemia (ALL) is a cancer of the blood and bone marrow,
that accounts for about 27% of all pediatric cancers worldwide1. Based on immunophenotype,
ALL can be classified as B-cell ALL and T-cell ALL. B-cell ALL accounts for 80-85% of
childhood ALL, including several subtypes as early precursor B (also called pro-B ALL),
common ALL, Pre-B ALL and Mature B-cell ALL. T-cell ALL only accounts for 15-20% of
childhood ALL. ALL can also be classified as low, standard, high and very high risks; Low risk
children are diagnosed with favorable age (1-10 years), White Blood Count (WBC) count<
50,000/microL and favorable cytogenetics changes, such as hyperdiploidy, presence of
ETV6_RUNX1 rearrangement and rapid response to treatment. Standard risk includes patients
with favorable age and low WBC count and rapid response to treatment, but without favorable
cytogenetic changes. High risk includes those who are diagnosed at age of 10-13 years, with
unfavorable cytogenetics changes and residual disease remaining in the bone marrow after
induction (minimal residual disease (MRD) >0.01 % at day 28 to 36 of therapy). Very high risk
include those with extreme hypodiploidy (44 or fewer chromosomes), t(9;22) (Philadelphia
chromosome) BCR/ABL1 rearrangement, t(4;11) KMT2A (MLL) rearrangement, iAMP21
(intrachromosomal amplification of chromosome 21) amplification, those over 13 years of age in
the United States, and/or failure to achieve complete remission at the end of induction therapy
(>5 % lymphoblasts in day 28 bone marrow or the presence of MRD).2,3
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One of the major challenges in treating childhood ALL has been control of relapse in the
central nervous system (CNS).4 Patients with CNS involvement (≥ 5 WBC/mul CSF with blast
cells) or traumatic lumbar puncture with blasts (TLP), T-cell immunophenotype, chromosome
translocations of t(9:22) (Philadelphia chromosome) and t(4;11) are associated with high risk of
CNS relapse.4 Several landmarks characterize the evolution of therapy for childhood ALL.5
Pinkel and colleagues developed four components of ALL treatments, including remission
induction, including central-nervous-system (CNS)-directed therapy with cranial radiation
therapy (CRT) and intrathecal methotrexate intensification (consolidation) therapy, and
continuation treatment, which improved the survivor rate from 10% to over 40%. Since then,
remarkable progress has been made in the treatment of childhood acute lymphoblastic leukemia
(ALL) during the past 50 years, and 5-year survival rates have improved to over 90% today.5
It has been shown that CRT is associated with acute neurotoxicity and long-term adverse
effects, such as CNS relapse6 and neurocognitive dysfunction, where higher doses of radiation
[e.g. >24 Gy] are associated much higher risk of severe neurocognitive impairment.7,8 In later
treatment protocols, such as COG AALL0232 protocol (High risk B-precursor ALL) 18 Gy
cranial RT was used for CNS 3 disease, and 12 Gy was used for CNS 1-2 to reduce
neurotoxicity. Studies from Dana-Farber Cancer Institute Consortium Protocol 87-01 and
Children’s Cancer Study Group (CCSS) showed excellent efficacy and limited late neurotoxicity
treated with 18 Gy CRT.9,10 Intrathecal therapy with methotrexate, hydrocortisone and
cytarabine, and intermediate-dose intravenous methotrexate11 replaced CRT in low- and then
standard-risk protocols to reduce short- and long-term neurotoxicity.12
In the St. Jude the Total Therapy XV protocol for childhood ALL, patients were treated
with intensification of systemic and intrathecal chemotherapy to avoid cranial radiation while
2

minimizing the risk of CNS relapses. Treatment included window therapy, induction (6-7
weeks), consolidation (8 weeks), and continuation (120 weeks for girls and 146 weeks for boys).
The goal of the induction phase (6-7 weeks) is to eradicate more than 99% of leukemic cells, key
chemotherapy agents include glucocorticoids, vincristine, and asparaginase and/or anthracycline.
The consolidation therapy phase includes intrathecal and high doses of intravenous methotrexate
to eradicate residual leukemic cells. During the continuation or maintenance phase (120 weeks),
patients received intrathecal and oral doses of methotrexate treatment as well as oral
mercaptopurine. 13,14 The 5-year overall survival rate for St. Jude XV (Table 1 for treatment
schema) was 93.5%, which was superior to the results of all major studies reported before. The
study concluded that prophylactic cranial irradiation could be safely omitted from the treatment
of childhood ALL.13
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Table 1. TOTXV Treatment schema
Treatment Phases
Upfront Window
Induction
(6-7 wks)
Consolidation
(8 wks)
Reintensification
Reinduction I
(Continuation wks 79)
Reinduction II
(Continuation wks 1719)
Continuation (120
wks girls/ 146 wks
boys)

Chemotherapy Agents
Low Risk
Standard/High Risk
HDMTX + LV + IT ARA-C
Pred, VCR, DNR, ASP, CYCLO, ARA-C, 6-MP, IT MHA (1 dose;
additional IT HMA on days 8 and 26 based on disease severity)+ LV
HDMTX, IT MHA (4 doses) +
HDMTX, IT MHA (4 doses) + LV,
LV, 6-MP
6-MP
NA
High Risk only: DEX, ARA-C, VP16, ASP, IT MHA (1 dose)
DEX, VCR, ASP, DOX, IT
DEX, VCR, DOX, ASP, IT MHA
MHA (1 dose)
(1 dose)
DEX, VCR, ASP, DOX, IT
MHA (1 dose)

DEX, VCR, ASP, IT MHA (1
dose), HD ARA-C

6-MP, DEX, VCR, MTX, IT
DEX, DOX, VCR, 6-MP, ASP, IT
MHA (5/8 doses based on disease MHA (10/14 doses based on
severity)
disease severity), MTX, CYCLO,
ARA-C
Key: HDMTX= high dose methotrexate; IT ARA-C=intrathecal cytarabine; LV=leucovorin;
PRED=prednisone;VCR=vincristine; DNR=daunorubicin; ASP=L-asparaginase;
CYCLO=cyclophosphamide; ARA-C=cytarabine; 6-MP=6-mercaptopurine; IT
MHA=intrathecal methotrexate + hydrocortisone + cytarabine; DEX=dexamethasone; VP16=etoposide; DOX=doxorubicin; MTX=methotrexate

Like St. Jude XV protocol, contemporary chemotherapy treatment of ALL includes
glucocorticoids, vincristine, L-asparaginase, anthracyclines and methotrexate.13,14 Methotrexate
is an indispensable component of modern treatment protocols; it is often administered directly to
the central nervous system (CNS) through intrathecal injections or intravenously to the systemic
circulation in high doses. In high doses, methotrexate can cross the blood brain barrier and cause
direct injuries to cells in the central nervous system. Folate deficiency following methotrexate
administration leads to increased serum homocysteine levels, which can damage the brain
cerebral vasculature, resulting in long-term neurocognitive disfunction.15
4

Part II Survivorship Morbidity – Neurocognitive Functions Outcomes
Significant neurocognitive function outcomes among those treated with contemporary
protocols compared to the outcomes treated on protocols that used CRT. These contemporary
protocols, however, still resulted in neurocognitive impairment rates that were still much higher
than those expected in the general population.15 In the St. Jude Total XV study, when evaluated
at 120 weeks after completion of consolidation therapy, ALL patients with higher intensity
chemotherapy (Standard/High Risk Arm), compared to lower intensity therapy (Low Risk Arm),
performed significantly worse on measures of processing speed and academic abilities and had
higher frequencies of hyperactivity and learning problems from parents reports.16

Executive functions (EFs) are one of the key components of neurocognitive function
often identified as impaired in long-term survivors of childhood ALL. EFs include cognitive
processes that are responsible for goal-directed behaviors and are organized by function within
the prefrontal cortex (PFC)17. There are three core abilities within executive functions: inhibition,
working memory, and cognitive flexibility. Inhibition includes resisting temptations to act
impulsively, interference control or selective attention, and control of distracting thoughts.
Working memory involves holding information in one’s mind and mentally manipulating the
information. Cognitive flexibility or shifting includes seeing things from different perspectives,
and quickly and flexibly adapting to changes in circumstances.18 These core abilities give rise to
higher order execution functions: reasoning, problem solving and planning18. These higher-order
EFs are very important, as they may affect a person’s educational attainment, employment, and
social functions.
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Cognitive and neuropsychological assessments show that although EFs emerge during the
first few years of life, they continue to strengthen significantly throughout childhood and
adolescence.17 The three core EFs show different trajectories during development, where
Inhibition appears to show particularly striking improvement during the preschool years and less
change later on. Working memory and Shifting show more gradual linear improvement
throughout development.17 Studies using magnetic resonance imaging of the brain have shown
that the PFC development consists of both progressive (e.g., myelination, neuron proliferation,
synaptogenesis) and regressive changes (e.g., cell death, synaptic pruning), and the PFC matures
later in adolescence as evidenced by further loss of gray matter.17
Sustained attention and processing speed are two other fundamental components of
neurocognitive functioning. Sustained attention is characterized by an individual’s ability to
direct and focus on one specific task for a continuous amount of time without being distracted.19
Sustained attention begins development early in life and is important for future development of
executive function abilities.20 Neuroimaging studies have shown that frontal and parietal cortical
areas, mostly in the right hemisphere, are activated during sustained attention performance. 19
Processing speed refers to the speed at which an individual completes basic cognitive
tasks, 21 which is a key cognitive resource and plays a crucial role in all types of cognitive
performance.22 Processing speed shows initially rapid improvement followed by gradual
improvements through childhood until the middle of adolescence, and then gradually declines
through adulthood.23 21 Various brain areas are activated when conducting different processing
speed tasks, e.g. visual-related areas (posterior regions of the right hemisphere) 24 is associated
with visual reaction time, fronto-parietal cortical network is associated with digit symbol task.25
However, white matter volume is shown to be associated globally with processing speed
6

performance regardless of the type of processing speed task.22In a longitudinal study of children
treated on a Children’s Oncology Group (COG) protocol, neurocognitive performance was
measured within two months of diagnosis and annually until one year after treatment. Verbal and
visual working memory, and motor speed declined within the first year of therapy, and this
decline predicted visual–motor integration problems off therapy.26 In a large cohort of adult
survivors of childhood ALL who survived at least 10 years, survivors who did not receive CRT
showed a higher frequency of severe impairment in executive function (flexibility and fluency),
processing speed (motor), attention (focus, sustain, and variability), and memory (new learning,
short-term and long-term recall) compared to population normative data. They also demonstrated
more problems with behavioral regulation (inhibition, shift, emotional control, self-monitor) and
meta-cognition (working memory, planning, task completion and organization).7

Part III Survivorship Morbidity –Behavior/Emotional outcomes
Long-term childhood cancer survivors from contemporary treatment also experience
behavior and emotional problems.27-29 Emotional problems can be characterized by anxiety (e.g.
generalized anxiety disorder, post-traumatic stress disorder, social phobia and specific phobia)
and depression (e.g. major depression disorder or dysthymia, bipolar I or II, or suicidal
ideation)30. Behavior problems can present as social withdrawal, attention problems, or
externalizing symptoms (e.g. hyperactivity, aggression, oppositional defiant disorder, or conduct
disorder (CD)).31
The emotional and behavioral development occurs along with cognitive development
from childhood through adolescents. Abnormal development in emotional or behavioral function
may lead to disorders that are commonly studied in normal population, including anxiety
7

disorder (e.g. Obsessive–compulsive disorder), Attention-Deficit/Hyperactivity Disorder
(ADHD), and aggressive behavior (e.g. Oppositional Defiant Disorder).
Attention-Deficit/Hyperactivity Disorder (ADHD) comprises a deficit in behavioral
inhibition that emerges early in childhood, is fairly persistent over development, and is linked to
executive function deficits.32 ADHD includes three subtypes, inattentive, hyperactive/impulsive,
or combined, with symptoms outlined in the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV).33 Individuals need to meet at least six of the nine
inattentive symptoms, six of the nine hyperactive/impulsive symptoms, or both categories of
inattentive and hyperactive symptoms, to be classified to three subtypes.33 ADHD occurs in
approximately 3-7% of the childhood population with boys being over represented 3:1, and the
disorder persists into adolescence in 50-80% of cases.32,34 ADHD is associated with weaker
function and structure of PFC circuits, especially in the right hemisphere.35
Obsessive–compulsive disorder (OCD) is a chronic and debilitating anxiety disorder that
affects between 1-3% of the general population, with a peak age of onset of 10-11 years.36-38
Obsessions are “repetitive, intrusive, and distressing thoughts, ideas, images, or urges that often
are experienced as meaningless, inappropriate, and irrelevant, but persist despite efforts to
suppress, resist, or ignore them”.31 Compulsions are “repetitive, stereotyped behaviors and/or
mental acts that are used to diminish the anxiety and distress associated with obsessions”.31
Children and adolescents with OCD often manifest multiple obsessions and compulsions at the
same time, with cleaning, repetition, checking and aggressive thoughts being most common.38
Meta-analysis of OCD functional neuroimaging studies linked the orbital–frontal gyrus (within
the frontal lobe) and the head of the caudate nucleus to OCD.36 Anxiety disorders, ADHD and
aggressive behavior are among the most common comorbidities of OCD in children and
8

adolescents.37 No study has reported the prevalence of OCD among long-term survivors of
childhood ALL.
The Diagnostic and Statistical Manual of Mental Disorders33 defines oppositional defiant
disorder (ODD) as a “pattern of negativistic, hostile, and defiant behavior” toward authority
figures continuing for at least 6 months and resulting in significant impairment in functioning39.
DSM-IV ODD diagnosis requires the presence of at least four of eight discrete symptoms in
angry and irritable mood (“often loses temper, is often touchy or easily annoyed by others, and is
often angry and resentful”), or argumentative and defiant behavior (“often argues with adults or
people in authority, often actively defies or refuses to comply with adults' requests or rules, often
deliberately annoys people and often blames others for his or her mistakes or misbehavior”), or is
“often spiteful or vindictive”.31 The prevalence of ODD is reported to be 8.3% (SE 0.7%) for
adolescents, age 13-17 years, from the US National Comorbidity Survey.34 Other studies have
shown prevalence varies from 2.7-6.0% among those aged 4-17 years.40 The median age-ofonset for ODD is 12 years (IQR 7-13 years) with median duration of 6 years. ODD is
significantly comorbid with every other lifetime DSM-IV disorders.41 A meta-analysis
demonstrated that patients with ODD present with brain abnormalities in bilateral amygdala,
bilateral insula, right striatum and left medial/superior frontal gyrus as well as the left precuneus.
These areas are involved in emotion-processing, error monitoring, self-control, and empathic and
social behavior.39 The symptoms in children and adolescents with ODD result in difficulties in
learning socially accepted behaviors and reactions, attributing hostile intentions to others, and
preferring aggressive solutions to social dilemmas.39 The prevalence of ODD in adolescent longterm survivors of childhood ALL is unclear.
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In one study conducted within the Childhood Cancer Survivor Study (CCSS), long-term
survivors of childhood leukemia treated with chemotherapy only showed that corticosteroids
such as prednisone were associated with externalizing symptoms compared to treatment without
corticosteroids, whereas, treatment with ≥ 4.3 g/m2 intravenous methotrexate was associated with
both global symptoms (internalizing as well as externalizing symptoms).27 Another study
conducted within the CCSS cohort showed that survivors of childhood ALL treated with
chemotherapy only reported a significantly higher frequency of inattention-hyperactivity, social
withdraw and learning problems compared to siblings, and increased cumulative dose of
intravenous methotrexate was associated with an increased risk of inattention-hyperactivity.29
The prevalence of attention-deficit/hyperactivity disorder (ADHD) among long-term ALL
survivors treated at St. Jude was found to be comparable to the general population, with the
majority of affected survivors having primarily attentive problems rather than hyperactivity.
Twenty-five percent of survivors reported an adverse impact of the attention problems on
functional limitations in daily activities, even though they did not meet ADHD diagnosis
criteria.42
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Chapter 2
EVOLUTION OF NEUROCOGNITIVE FUNCTION IN LONG-TERM SURVIVORS OF
CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH
CHEMOTHERAPY ONLY
Introduction
Contemporary chemotherapy results in 5-year survival of greater than 90% for children
with acute lymphoblastic leukemia (ALL) without the use of cranial radiation therapy (CRT).13,43
Compared to survivors treated on older protocols that included CRT, neurocognitive outcomes
for survivors treated with chemotherapy only have significantly improved, but problems are still
identified at a higher frequency than that expected in the general population.15,44
Cognitive problems emerge early during the course of chemotherapy-only treatment for
childhood ALL. Compared to normative data, ALL survivors demonstrate lower verbal and
visual working memory, and slower motor speed after completion of induction therapy, which
predict decline in visual–motor integration skills over time.26 By the end of therapy, all survivors
appear to be at risk for problems in sustained attention, and those treated on higher risk protocols
are reported by parents to have more problems with inattention compared to survivors treated on
low risk protocols.16,45
Neurocognitive problems in long-term survivors of childhood ALL are often
concentrated in higher order cognitive abilities (i.e., executive function).15 Among young adult
survivors of childhood ALL who were treated with chemotherapy-only and who were at least ten
years from diagnosis, the frequency of severe impairment in executive function was eight times
higher than that seen in the general population.44 Although higher plasma concentration of
methotrexate and homocysteine are associated with lower executive function in long-term
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adolescent survivors,46 some studies failed to identify treatment- or disease-related factors
associated with executive function problems.47
With typical development, executive functions emerge early in childhood and continue to
strengthen throughout adolescence.48 These executive functions begin with core skills in
inhibitory control, attention and working memory,18 and evolve into the higher order abilities of
cognitive fluency, flexibility, planning, organization and abstraction.49 Impairment in core skills
may limit development of the higher order abilities.
The aim of this study was to evaluate the association between sustained attention and
parent-rated behavioral inattention at the end of chemotherapy, with neurocognitive outcomes
(i.e. executive function, sustained attention and processing speed) at long-term follow-up. We
were interested in determining whether specific chemotherapeutic exposures independently
predict neurocognitive impairment at both short-term and long-term follow-up, and whether
short-term attention and behavioral problems evolve into long-term problems with executive
function. If long-term neurocognitive outcomes are predicted by end of therapy symptoms, these
early symptoms may serve as a marker for those at greatest risk and in most need of early
intervention.

Method
Patients
This study was approved by the institutional review board at St. Jude Children’s Research
Hospital and informed consent was obtained from the parents and assent from the survivors, as
appropriate.
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From 2000 to 2010, 408 children with ALL were treated at St. Jude Children’s
Research Hospital on the Total Therapy XV protocol (ClinicalTrials.gov,
NCT00137111).13 For end-of-therapy assessment, survivors had to be in continuous complete
remission, not have a pre-existing non-cancer related neurodevelopmental or genetic disorder
associated with cognitive impairment, not have a brain injury unrelated to their cancer, and be
proficient in English. There was a total of 262 survivors evaluated at the end of therapy. To be
eligible for long-term follow-up assessment, survivors must have been more than five years from
diagnosis and more than eight years of age (to reliably and uniformly assess executive function
abilities), remained in continuous complete remission, and not experienced an unrelated brain
injury after cessation of therapy. There were 220 survivors eligible for long-term follow-up
assessment, 158 survivors participated (72%; see Figure 1) and provided evaluable data.
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Figure 1. Consort Diagram (Study 1)

Per the Total Therapy XV protocol, all children received high-dose intravenous
methotrexate (HD-MTX), triple intrathecal treatments (methotrexate, hydrocortisone, cytarabine)
and oral dexamethasone, in addition to other chemotherapeutic agents. Children in the low-risk
and standard-risk arms were treated with four doses of HD-MTX at 2.5 gm/m2 and 5 gm/m2 per

14

dose, respectively. Blood samples were drawn before HD-MTX infusion and at six, 23, and 42
hours following the start of each HD-MTX course and methotrexate concentrations measured by
fluorescence polarization immunoassay (TDx/TDxFLx Systems, Abbot Laboratories, Abbot
Park, IL, USA) , Exposures were quantified using area-under-the-curve (AUC) methods.
Leucovorin rescue (10 to 15mg/m2) started 42 hours after HD-MTX and repeated every six hours
for a total of five doses. Prophylactic CRT was not administered to any patient, regardless of
presenting features, including the presence of CNS leukemia at diagnosis.

Neurocognitive Testing

Sustained attention and parent-reported behavior problems were evaluated at 120 weeks
post completion of consolidation (end of therapy) using standardized measures with
demonstrated reliability and validity. Patients completed a computerized sustained attention
measure (Conners' Continuous Performance Test CPT II),50 which yields scores for omissions,
commissions, variability, detectability, and a risk taking response style. CPT II respondents are
required to press the space bar whenever any letter except the letter ‘X’ appears on the computer
screen. The test structure consisting of 6 blocks and 3 sub-blocks, each containing 20 trials (letter
presentations). Omissions are the number of targets to which the individual did not respond.
Commissions are the number of time the individual responded to a nontarget ("X"). Evidence of
inattention may be presented by slow or variable reaction time, or with an elevated number of
omission and commission errors. Impulsivity pattern may displayed through fast reaction times
combined with a high number of commission errors. Variability in the standard error of reaction
times measures "within respondent" variability (i.e., the amount of variability the individual
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shows in relation to his or her own overall standard error). Detectability is a measure of how well
the individual discriminates between the target (non-X) and non-target (X), which provides a
means of assessing discriminative power. Risk taking response style allows for evaluation of the
speed/accuracy trade-off.
Parents completed standardized ratings of child behavior (Conners' Parent Rating Scale
CPRS) resulting in five scales, including conduct problems, inattention, somatic symptoms,
anxiety, and hyperactivity/ impulsivity, and each scales include several items 51Conduct
problems include 10 item such as “Angry and resentful”. “Fight”, “Argues with adults”, “Losses
temper”, “Irritable”, children with high scores are likely to break rules, have problems with
persons in authority and are more easily annoyed and angered than most of their age. Inattention
or cognitive problem includes 12 items, such as “Fails to give close attention to details or makes
careless mistakes in schoolwork, work or other activity”, or “Fails to complete assignments”,
children with high scores maybe inattentive or have problems organizing their work, or have
trouble concentrating on tasks. Psychosomatic symptoms include 6 items including “Stomach
aches”, “Complains about being sick even when nothing is wrong”, children with high scores
report more physical symptoms. Anxiety includes 8 items such as “Timid, easily frightened”,
“Afraid of people”, “Has a lot of fears”, children with high score usually have more worries and
fears than most of their age, and are prone to be emotional and appear to be very shy and
withdrawn. Hyperactivity/Impulsivity include 9 items, such as “Is always “on the go” or acts as
if driven by a motor”, “Excitable, impulsive”, children with high scores have difficulty sitting
still, feel more restless and impulsive.
At long-term follow-up, the Delis-Kaplan Executive Function System (DKEFS)52 was
used to assess cognitive flexibility (Number letter Switching, connecting numbers and letters in
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alternating sequential order (1-A-2-B-3-C...) ), letter fluency (required to state as many words as
s/he could that begin with the specified letter within 60 seconds; with a total of three letters are
given) , number sequencing (connecting numbers in sequential order), letter sequencing
(connecting letters in sequential order), planning (Tower, using disks and pegs to build a tower
as the picture of a tower to be built), and problem solving abilities (Abstraction, 20 questions – to
ask fewest number of yes/no questions to identify the unknown target object presented with a
stimulus page depicting pictures of 30 common objects). The Wechsler Intelligence Scales 53,54
were used to assess verbal span (Digit Forward, to repeat the number sequence in the same
order), verbal working memory (Digit Backward, to repeat the number sequence in the reverse
order), and Spatial Span Forward (to touch board with blocks in the same order as the examiner
does), and Spatial Span Backward for (to touch board with blocks in the reverse order as the
examiner does). Processing speed includes visual (Symbol Search, to find matched symbols)
and visual-motor (Digit Symbol, to copy abstract symbols). Rey Complex Figure Copy55 (to
copy a complex figure) was used to measure organization skills. Grooved Pegboard Test (to put
pegs into grooved board using the dominant and non-dominant hand, respectively) was used and
fine motor dexterity skills.56 The same sustained attention measure included at end of therapy
was administered at long-term follow-up.50
Statistical Analysis
For demographic and clinical variables, means and standard deviations were calculated
for continuous variables and two-sample t-tests, frequencies and Chi-Square tests were applied
for categorical variables to compare participant and non-participants. Behavioral and
neurocognitive scores were transformed into age-adjusted Z-scores (μ=0, σ=1.0) using national
normative data. One-sample t-tests were applied to compare mean survivor performances (z-
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score ≤ -1.286) and parent reports (z-score ≥ 1.286), and one sample binomial tests were applied
to compare survivor performance impairment with that of population norms (i.e. 10% of
normative sample expected). All p-values were adjusted by controlling false discovery rate using
SAS MULTTEST procedure.
Among those end of therapy and long-term follow-up variables that were significantly
different from population norms, for both mean scores and proportion impaired, general linear
models (GLM) were used to identify associations with pre-defined pharmacological
predictors44,46 (HD-MTX exposure, number of intrathecal injections), adjusting for age at
diagnosis and parents’ education. Correlation analyses were applied to test associations between
sustained attention and parent-rated behavior problems at the end of therapy with long-term
neurocognitive outcomes. Degree of change in sustained attention z-score from end of therapy to
long-term follow-up was tested using a one sample t-test, and the average changes were
compared between males and females using two-sample t-tests. For any end of therapy outcomes
that were significantly associated with pharmacological predictors and with long-term outcomes,
mediation analysis was conducted to assess if the pharmacological effect on long-term outcomes
was mediated by end of therapy function. Statistical significance level was set to 0.05. All
analyses were conducted in SAS (SAS 9.4, SAS Institute, Cary NC) or STATA 13.1 (StataCorp
LP, College Station, TX).
Results
Characteristics of the eligible study population are presented in Table 2. There were no
significant differences observed between participants and non-participants in demographics, risk
stratum or cumulative drug doses. Of the 158 participants, 52% were females, 77% were White,
and 43% were treated on the standard-risk arm.
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Table 2: Demographics and treatment characteristics of participants and non-participants
Participants (N=158)

Non-Participants (N=62)

No.

%

No.

%

Female

82

51.9

24

38.7

Male

76

48.1

38

61.3

White

122

77.2

48

77.4

Other

36

22.8

14

22.6

Years

158

13.7 (4.6)

Years

155

13.9 (2.6)

Years

150

13.7 (3.0)

158

6.6 (4.5)

157

7.6 (1.7)

Mean (SD)

Pa

Mean (SD)

Demographics
Sex

Race
Age at LongTerm Followup
Maternal
education
Paternal
education

Treatment characteristics
Age at
Years
diagnosis
Time from
diagnosis to
Years
Long-Term
Follow-up
Risk

HD-MTX

62

0.97

6.7 (4.7)

Low

90

56.96

33

53.2

Standard/
High

68

43.04

29

46.8

AUC

155

33.1 (12.0)

0.08

0.92

0.62
33.5 (11.7)

0.82

IT
No.
158
14.7 (4.0)
14.9 (3.9)
0.71
chemotherapy* counts
Pa Chi-Square test or two sample t-test p-values
Abbreviations: HD-MTX AUC, high dose IV methotrexate plasma concentration (area under
curve [AUC]; IT, intrathecal; SD, standard deviation
*IT MHA, intrathecal injection of MTX plus hydrocortisone plus cytarabine

At the end of therapy, sustained attention and parent-reported behavior problems were
significantly worse than the population mean, with a higher proportion of impairment than the
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10% expected in omissions, variability, detectability, and risk taking, as well as parent-reported
attention problem, somatic symptoms and anxiety (all p-values <0.05, Table 3).

Table 3. End-of therapy and long-term follow-up outcomes (n=158) compared to population
norms

End of Therapy
Sustained Attention
Omissions
Commissions
Variability
Detectability
Risk Taking
Parent-reported Behavior
Conduct
Inattention
Somatic
Hyperactivity/
Impulsivity
Anxiety
Long-term Follow-up
Executive Function
Abstraction
Planning
Inhibitory control
Cognitive flexibility
Letter fluency
Category fluency
Organization
Verbal working memory
Spatial working memory
Spatial construction
Attention
Verbal span
Spatial span
Omissions
Commissions

Mean (SD)

Pa

Impaired
N (%)

Impaired
95% CI
(%)

Pb

-1.20 (0.88)
-0.15 (1.02)
-0.84 (1.34)
-0.98 (1.15)
-2.09 (2.02)

<0.0001
0.19
<0.0001
<0.0001
<0.0001

51 (48.6)
11 (10.5)
41 (39.0)
40 (38.1)
56 (53.3)

38.7 - 58.5
5.3 - 18.0
29.7 - 49.1
28.8 - 48.1
43.3 - 63.1

<0.0001
0.44
<0.0001
<0.0001
<0.0001

-0.00 (1.07)
0.27 ( 1.36)
1.76 ( 1.90)

0.97
0.025
<0.0001

0.03 ( 1.07)

0.77

17 (11.6)
29 (19.9)
74 (50.7)
23 (15.8)

6.9 - 18.0 0.28
13.7 - 27.3 0.00007
42.3 - 59.0 <0.0001
10.3 - 22.7
0.015

0.24 ( 0.94)

0.005

22 (15.1)

9.7 - 21.9

0.025

-0.22 ( 0.95)
-0.02 ( 0.95)
-0.14 ( 1.01)
-0.45 ( 1.15)
-0.35 ( 1.00)
0.07 ( 1.07)
-2.19 ( 2.34)
-0.14 ( 0.99)
0.08 ( 0.91)
-0.18 ( 1.00)

0.015
0.84
0.17
0.00001
0.00013
0.48
<0.0001
0.16
0.40
0.06

26 (16.8)
19 (12.3)
24 (15.7)
38 (24.2)
32 (20.5)
21 (13.5)
83 (53.5)
20 (12.8)
17 (10.9)
24 (15.4)

11.3 - 23.6
7.5 - 18.5
10.3 - 22.4
17.7 - 31.7
14.5 - 27.7
8.5 - 19.8
45.4 - 61.6
8.0 - 19.1
6.5 - 16.9
10.1 - 22.0

0.0083
0.21
0.027
<0.0001
0.00003
0.117
<0.0001
0.17
0.37
0.028

-0.31 ( 0.98)
-0.13 ( 0.94)
-0.27 ( 1.61)
-0.16 ( 1.22)

0.0005
0.19
0.09
0.19

29 (18.6)
23 (14.6)
23 (15.0)
19 (12.4)

12.8 - 25.6
9.5 - 21.2
9.8 - 21.7
7.6 - 18.7

0.00078
0.048
0.038
0.20
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Table 3. (Continued.) End-of therapy and long-term follow-up outcomes (n=158) compared to
population norms

Mean (SD)

Pa

Impaired
N (%)

Impaired
95% CI
(%)
9.8 - 21.7
6.6 - 17.2
4.1 - 13.3

Variability
-0.08 ( 1.23) 0.53
23 (15.0)
Detectability
-0.13 ( 1.22) 0.30
17 (11.1)
Risk Taking
-0.08 ( 0.97) 0.40
12 ( 7.8)
Processing speed
Word reading
-0.09 ( 0.92) 0.35
16 (10.4)
6.1 - 16.3
Color naming
-0.11 ( 0.91) 0.19
22 (14.3)
9.2 - 20.8
Number sequencing
-0.15 ( 0.99) 0.14
25 (15.9)
10.6 - 22.6
Letter sequencing
27 (17.2)
11.6 - 24.0
-0.25 ( 1.06) 0.015
Motor speed
35.1 - 51.1
-1.31 ( 1.59) <0.0001 67 (42.9)
Visual-motor speed
10.1 - 22.0
-0.33 ( 0.96) 0.00013 24 (15.4)
Visual speed
0.06 ( 0.98) 0.57
18 (11.5)
6.9 - 17.5
a
P p-value based on t-test with correction for false discovery rate.
Pb p-value based on binomial test with correction for false discovery rate.
Abbreviations: SD, standard deviation; CI, confidence interval.

Pb
0.038
0.36
NA
0.44
0.064
0.020
0.0051
<0.0001
0.028
0.30

Long-term follow-up neurocognitive measures were significantly below the population
mean, with a higher proportion of impairment than the expected 10%, on measures of executive
function (abstraction, cognitive flexibility, letter fluency organization), attention (verbal span)
and processing speed (letter sequencing, motor speed and visual-motor speed), with all p-values
<0.05, Table 2). Survivors improved on measures of sustained attention by an average of one to
two standard deviations from end of therapy to long-term follow-up, and females demonstrated
slightly more improvement than males (Figure 2).
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Figure2. Change in sustained attention z-score from end of therapy to long-term follow-up. On
the left, change in sustained attention z-score from end of therapy to long-term follow-up. Each
individual survivor is plotted in the figure, with scores above zero representing improvement and
scores below zero representing decline. Survivors improved by an average of 1 to 2 standard
deviations from end of therapy to long-term follow-up. The blue lines and error bars showed the
mean and 95% CL of z-score changes. On the right, mean and 95% CL for change in sustained
attention from end of therapy to long-term follow-up stratified by sex. Females demonstrated
slightly more improvement than males.

Parent-reported inattention at the end of therapy was positively associated with HD-MTX
exposure (p=0.009) and number of IT injections (p=0.002, Table 4). HD-MTX exposure and
number of IT injections were also associated with cognitive flexibility, omissions and visualmotor processing speed at long-term follow-up, with all p-values <0.05 (Table 5).
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Table 4. Effect of pharmacological predictors on sustained attention and parent-reported
behavior problems at the end of therapy

Sustained Attention
Omissions
Variability
Detectability
Risk Taking

HD-MTX
Est.
SE
-0.013
-0.020
-0.009
-0.033

0.008
0.011
0.010
0.018

p-value

IT Chemotherapy
Est.
SE

p-value

0.11
0.081
0.35
0.063

0.007
0.032
0.049
0.025

0.79
0.38
0.10
0.66

0.025
0.036
0.030
0.056

Parent-reported Behavior
Inattention
0.025
0.009
0.091
0.029
0.009
0.002
Psychosomatic
0.011
0.014
0.45
0.073
0.044
0.096
Hyperactivity/Impulsivity
0.018
0.007
0.044
0.023
0.059
0.014
Anxiety
0.007
0.007
0.32
0.017
0.021
0.42
(Models adjust for parents’ Highest Education level and age at diagnosis)
Abbreviations: HD-MTX = high dose intravenous methotrexate exposure, quantified in plasma
as area under the curve; IT = intrathecal; Est. = Parameter estimate; SE = standard error
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Table 5. Effect of pharmacological predictors on neurocognitive outcomes at long-term followup
HD-MTX
Est.

IT Chemotherapy
SE

pvalue

Est.

SE

p-value

Executive Function
Abstract
-0.002
0.007
0.74
-0.005
0.020
0.78
Cognitive Flexibility -0.025
0.007
0.023
0.0008 -0.054
0.0197
Letter fluency
-0.013
0.007
0.053
0.002
0.020
0.92
Organization
-0.012
0.016
0.46
-0.062
0.049
0.20
Spatial construction
-0.011
0.006
0.08
-0.025
0.019
0.21
Attention
Verbal span
-0.009
0.007
0.16
-0.016
0.020
0.43
Omission
-0.035
0.011
0.033
0.0013 -0.069
0.035
Processing speed
Letter Sequencing
-0.016
0.007
-0.042
0.021
0.052
0.026
Motor Speed
-0.015
0.011
0.15
-0.056
0.032
0.08
Visual-motor speed
-0.016
0.006
-0.063
0.018
0.007
0.0006
*GLM model adjust for parents’ Highest Education level and age at diagnosis
Abbreviations: HD-MTX = high dose intravenous methotrexate exposure, quantified in plasma
as area under the curve; IT = intrathecal; Est. = Parameter estimate; SE = standard error

Sustained attention at the end of therapy was associated with letter fluency, motor speed
and visual-motor processing speed at long-term follow-up. Parent-reported inattention at the end
of therapy was associated with verbal span, motor speed and visual-motor processing speed at
long-term follow-up. Parent-reported hyperactivity/impulsivity at the end of therapy was
associated with cognitive flexibility, organization, verbal span, motor speed and visual-motor
processing speed at long-term follow-up (all p-values <0.05, Table 6).
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Table 6 Correlation of sustained attention and parent-reported behavior problems at the end of therapy with neurocognitive function at
long-term follow-up
End of Therapy
Sustained Attention

Parent-reported Behavior
Risk
Hyperactivity /
Long-term
Omissions Variability
Detectability
Inattention a
Taking
Impulsivity a
Follow-up
r (p)
r (p)
r (p)
r (p)
r (p)
r (p)
Abstraction
0.08 (0.40) 0.17 (0.09)
0.10 (0.30)
0.17 (0.08) 0.10 (0.22)
-0.04 (0.66)
Cognitive flexibility 0.10 (0.32) 0.10 (0.32)
0.14 (0.17)
0.12 (0.24) -0.09 (0.26)
-0.21 (0.01)
Letter fluency
0.18 (0.07) 0.16 (0.12)
0.24 (0.01)
0.24 (0.02) -0.05 (0.55)
-0.07 (0.39)
Organization
0.17 (0.09) 0.15 (0.14)
0.01 (0.93)
0.11 (0.28) -0.01 (0.94)
-0.20 (0.02)
Verbal span
0.13 (0.20) 0.04 (0.66)
0.08 (0.40)
0.07 (0.49) -0.17 (0.045)
-0.19 (0.02)
Letter sequencing
0.17 (0.09) 0.12 (0.24)
0.18 (0.07)
0.16 (0.12) -0.10 (0.23)
-0.09 (0.29)
Motor speed
0.20 (0.04) 0.07 (0.52)
0.31 (0.002)
0.23 (0.02) -0.18 (0.03)
-0.24 (0.00)
Visual-motor speed 0.15 (0.13) 0.24 (0.01)
0.23 (0.02)
0.07 (0.47) -0.29 (<0.0001) -0.22 (0.01)
Abbreviations: Pearson correlation coefficients (r) and p-values (p) under the null hypothesis of zero correlation.
a

Higher scores indicate worse outcomes.
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Anxiety a
r (p)
0.03 (0.76)
-0.09 (0.29)
0.08 (0.36)
-0.02 (0.85)
-0.09 (0.30)
0.00 (0.99)
0.05 (0.52)
-0.03 (0.73)

Based on mediation analysis (Table 7), the number of IT injections demonstrated a direct
effect on processing speed at long-term follow-up (β= -0.044, p=0.02), as well as an indirect
effect through parent-reported inattention (β= -0.013, p=0.04 Figure 3a). Only direct effects of
treatment exposure were identified for measures of executive function and attention at long-term
follow-up, suggesting that end of therapy performance and behavior did not mediate these
outcomes (Figure 3b).
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Table 7 Mediation Analysis
HD-MTX exposure
Direct Effect
Indirect Effect
Est
SE
p-value
Est
SE
Cognitive Flexibility
-0.032
0.008 <0.001
0.000
0.001
Letter fluency
-0.027
0.008 0.001
-0.001 0.001
Omission
-0.022
0.010 0.025
-0.002 0.002
Letter Sequencing
-0.021
0.008 0.007
0.000
0.001
Visual Motor Speed
-0.018
0.008 0.018
-0.001 0.001
Cognitive Flexibility
-0.023
0.008 0.004
-0.001 0.002
Letter fluency
-0.012
0.007 0.086
0.000
0.002
Omission
-0.037
0.011 0.001
0.002
0.003
Letter Sequencing
-0.016
0.008 0.037
-0.002 0.002
Visual-Motor Speed
-0.012
0.006 0.044
-0.004 0.002
Number of intrathecal injection
Direct Effect
Indirect Effect
Cognitive Flexibility Detectability
-0.073
0.027
0.003
0.004
0.008
Letter fluency
Detectability
-0.052
0.026
0.008
0.007
0.047
Omission
Detectability
-0.041
0.032
0.203
0.013
0.009
Letter Sequencing
Detectability
-0.040
0.025
0.111
0.004
0.005
Visual-Motor Speed
Detectability
-0.091
0.023
0.006
0.005
<0.0001
Cognitive Flexibility Inattention
-0.041
0.025
0.106
-0.005
0.007
Letter fluency
Inattention
0.011
0.023
0.635
-0.005
0.006
Omission
Inattention
-0.089
0.037
0.005
0.009
0.016
Letter Sequencing
Inattention
-0.040
0.024
0.095
-0.007
0.007
Visual-Motor Speed
Inattention
-0.044
0.019
-0.013
0.006
0.023
Abbreviations: Est, parameter estimate; SE, standard error
Long-term follow
up outcomes

End of
therapy
Mediator
Detectability
Detectability
Detectability
Detectability
Detectability
Inattention
Inattention
Inattention
Inattention
Inattention
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p-value
0.939
0.438
0.435
0.582
0.539
0.527
0.762
0.508
0.305
0.054

Total Effect
Est
SE
-0.032 0.008
-0.028 0.008
-0.024 0.010
-0.021 0.008
-0.019 0.008
-0.024 0.008
-0.013 0.007
-0.036 0.011
-0.018 0.007
-0.016 0.006

p-value
<0.001
0.001
0.018
0.006
0.014
0.002
0.068
0.001
0.018
0.009

0.549
0.217
0.167
0.357
0.256
0.421
0.448
0.568
0.294
0.042

Total Effect
-0.070 0.027
-0.044 0.026
-0.028 0.032
-0.036 0.025
-0.085 0.023
-0.047 0.025
0.006
0.022
-0.083 0.036
-0.047 0.023
-0.057 0.019

0.01
0.097
0.384
0.153
<0.0001
0.059
0.775
0.019
0.044
0.003

Figure 3a Mediation analysis. Mediation effect of intrathecal chemotherapy on processing speed
at long-term follow-up through parent-reported behavioral inattention at the end of therapy.
Direct effect: β= -0.044, p=0.02; Indirect effect: β= (0.089) × (-0.0147) = -0.013, p=0.04

Figure 3b Mediation analysis. No Mediation effect of chemotherapy on executive function at
long-term follow-up through behavior inattention at the end of therapy.

Discussion
We conducted a longitudinal study on the evolution of neurocognitive functions in a large
sample of long-term survivors of childhood ALL treated on a contemporary chemotherapy-only
regimen. Our novel results demonstrate that many survivors who have poor sustained attention at
the end of therapy significantly improved after long-term follow-up. While most survivors were
functioning well at long-term follow-up, a higher frequency of executive dysfunction and slow
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processing speed was identified compared to the general population. Parent-reported inattention
at end of therapy and direct assessment of executive dysfunction and slow processing speed at
long-term follow-up were associated with higher methotrexate exposure and a greater number of
intrathecal chemotherapy treatments. However, the executive function problems at long-term
follow-up were not dependent upon development of inattention at the end of therapy. These
findings suggest that patients who are going to receive higher concentrations of intravenous
methotrexate and more intrathecal treatments will be at greater risk for long-term neurocognitive
deficits, and thus should receive early therapeutic interventions during or shortly after active
chemotherapy treatment.
Executive function begins with development of self-regulation and inhibitory control
during early childhood.18,57 Self-regulation facilitates the development of attention and
behavioral control.32,58 With maturation, higher order executive functions like cognitive
flexibility and fluency develop.18,20 Impairment in basic skills, like attention, may limit the
development of these higher order functions. For this reason, we expected inattention at the end
of therapy to impact the development of executive function at long-term follow-up. In the current
study, many survivors demonstrated poor sustained attention at the end of therapy, though
significant improvements in these attention skills were observed after long-term follow-up. Many
survivors also demonstrated executive function problems during long-term follow-up, though
these problems were not dependent upon the earlier attention problems. The sustained attention
problems for some survivors identified by direct assessment at the end of therapy could be due to
acute reactions to treatment that recover over time and do not impact executive function at longterm follow-up. We have previously shown that some survivors demonstrate recovery of
cognitive problems from the beginning to the end of chemotherapy for childhood ALL.26
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At long-term follow-up, we found executive function problems to be much more
prevalent than attention problems. Previous research has shown that prefrontal cortex regions are
susceptible to HD-MTX exposure.46 These regions are involved in executive function
processes18,59 and mature over a longer period of time compared to many other brain regions.60
White matter volume reduced and leukoencephalopathy in this region have been demonstrated to
occur during chemotherapy and to be related to cognitive problems.61 This may suggest that the
chemotherapy impact on frontal lobe development may not be expressed through neurocognitive
problems until long-term follow-up. Related to this point, within our current sample, 52% of
those survivors who demonstrated executive dysfunction at long-term follow-up did not display
sustained attention problems at the end of therapy.
The current study showed an association between the number of triple intrathecal
injections and long-term processing speed was partially mediated through parent-reported
inattention behavior at the end of therapy. Higher scores on parent-reported inattention indicate
that parents perceive their children as having more problems “organizing their work”, more
difficulty “completing tasks or schoolwork”, and more trouble “concentrating on tasks that
require sustained mental effort”.51 Many of these behaviors may be impacted by not only
inattention, but also processing speed. For example, sustained mental effort will require longer
duration with slower processing speed, and schoolwork is more likely to be incomplete when
processing speed is slow. Thus, in rating their child’s inattention symptoms at the end of therapy,
parents may be picking up on subtle difficulties with processing speed as well. Parent-reported
inattention behavior may be useful as an early marker for long-term problems in processing
speed and task completion.
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Several limitations should be considered in the current study. There was no healthy
control group. However, we have a relatively large sample of childhood ALL survivors,
permitting within group comparison across treatment exposures. In addition, the primary focus of
the study was to determine how early attention problems evolve over time and, given the
longitudinal follow-up, tracking of survivor change from baseline was possible. An additional
limitation is that there was no pre-therapy testing of neurocognitive functions, which is difficult
to obtain in young children with this diagnosis. To account for this limitation, we adjusted
analyses for parent education, which should provide a reasonable surrogate for pre-morbid
potential.62 A final limitation was that we conducted a single site study, potentially limiting
generalization. However, the chemotherapy agents used in our protocol comprise the backbone
of contemporary protocols at most institutions.
In conclusion, the current study demonstrates an association between chemotherapy
exposure and short-term and long-term neurocognitive functions. Although short-term attention
problems are correlated with long-term neurocognitive outcomes, the attention problems do not
appear to evolve into executive function problems. Rather, both problems are driven by intensity
of chemotherapy treatment. Future prospective studies should consider preventative intervention,
particularly for those survivors who are going to be treated with more intensive chemotherapy
regimens. In addition, survivors of childhood ALL should be closely monitored for
neurocognitive problems well into long-term survivorship, regardless of whether they display
problems at the end of chemotherapy.
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Chapter 3
PARENT-REPORTED AND SELF-PERCEIVED BEHAVIORAL AND PSYCHIATRIC
SYMPTOMS IN LONG-TERM SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA TREATED WITH CHEMOTHERAPY ONLY
Introduction
Adolescent long-term survivors of childhood lymphoblastic leukemia (ALL) experience
psychosocial and behavioral problems, including symptoms of anxiety, depression, inattention,
and antisocial behavior63 either in isolation or as clusters of behavioral and emotional
symptoms.64,65 Long-term survivors of childhood ALL treated with only chemotherapy
demonstrate higher rates of headstrong behavior, inattention-hyperactivity, social withdrawal and
learning problems compared to healthy siblings, with higher risk of inattention-hyperactivity
symptoms associated with higher cumulative doses of intravenous methotrexate.29 Although the
rate of Attention-Deficit/Hyperactivity Disorder (ADHD) appears comparable to the general
population, a quarter of survivors report an adverse impact of behavioral symptoms on functional
impairment.42 There is evidence to suggest more emotional and behavioral symptoms in
survivors of childhood ALL compared to the general population, however, the prevalence and
severity of clinically diagnosed psychiatric disorders have not been well characterized in this
population.
Studies that evaluate the presence of emotional or behavioral morbidities typically rely on
self-report or proxy report of symptoms. This approach involves rating individual behaviors that
cluster in symptom domains such as inattention, hyperactivity/impulsivity, depression and
anxiety. However, the presence of symptoms alone may not be sufficient to warrant a formal
diagnosis or treatment of psychiatric disorders. The gold standard for systematic assessment of
psychiatric disorders involves the use of structured diagnostic interviews.66 For example, a rating
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scale may provide a norm-referenced level of inattentive behavior, whereas the clinical diagnosis
of ADHD requires not only the presence of sufficient symptoms, but also a minimum age at
symptom onset, minimum symptom duration, evidence of clinically significant impairment in
social, academic or occupational functioning, as well as differential diagnosis of conditions with
overlapping symptoms (e.g. learning disability, anxiety disorders).67 This formal diagnostic
process for psychiatric disorders has not been regularly utilized among long-term survivors of
childhood ALL.
There have been inconsistent reports pertaining to emotional distress in parents of
survivors of childhood cancer.68 Most parents of survivors of ALL treated on chemotherapy-only
protocols do not have elevated symptoms of anxiety, depression or post-traumatic stress
symptoms (PTSS); however subgroups of parents do report substantial symptoms of
psychological distress or PTSS.68,69 These symptoms of PTSS can persist many years following
the completion of therapy.70 Parental distress has been associated with their report of emotional
symptoms in child survivors of ALL, although it is unclear whether this distress impacts the
child’s emotional or behavioral symptoms.69 The association between parental emotional distress
or PTSS and behavioral problems in childhood cancer survivors requires further investigation.
The objectives of this study are (1) to examine the prevalence and pattern of parentreported and self-reported behavioral symptoms in long-term survivors of childhood ALL; (2) to
examine the prevalence of psychiatric disorders, diagnosed through structured diagnostic
interviews; and (3) to evaluate the impact of parent self-reported emotional distress and PTSS on
report of child behavioral symptoms and psychiatric disorders.
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Methods
Patients
Subjects included in this study were from the same group of survivors in the first study
with the same exclusion criteria. A total of 236 survivors were eligible for follow-up and 161
(68.2%) participated (Figure 4).

Figure 4. Consort Diagram (Study 2)
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Behavior Symptom Rating and Diagnostic Interviews
Data for self-reported child behavioral symptoms (Conners’ Rating Scale, 3rd edition71)
and parent-report of child behavioral and emotional symptoms (Behavior Assessment System for
Children [BASC-2]72), along with interview with parents for the Diagnostic Interview for
Children and Adolescents (DICA)73, were collected during the same visit. The Conners is a
multi-informant assessment of children and adolescents between 6 and 18 years of age that takes
into account home, social, and school settings. It includes specific questions to evaluate
symptoms of inattention (10 items, such as “Has trouble concentrating”, “Gives up easily on
difficult tasks”), hyperactivity/impulsivity (14 items, such as “Fidgeting”, “Is noisy and loud
when playing or using free time”, “Restless or overactive”, “Interrupts others”), learning
problems (9 items, such as “Spelling is poor”, “Does not understand what he/she reads”, “Needs
extra explanation of instructions”), anxiety (4 items, including “Worries about many things”,
“Has trouble controlling his/her worries”, “Appears “on edge”, nervous or jumpy”, “Becomes
irritable when anxious”), depression (4 items, including “Feels worthless”, “Seems tired; has low
energy.”, “Has lost interest or pleasure in activities”, “Is sad, gloomy, or irritable for many days
at a time”), defiance/aggression (14 items, such as “Bullies, threatens, or scares others”, “Is coldhearted and cruel”, “Tells lies to hurt other people”) , and symptom profiles consistent with
DSM-IV diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) hyperactive Impulsive
type (11 items, such as “Fidgets or squirms in seat”, “Restless or overactive”, “Talks too much”)
and inattentive type (10 items, such as “Doesn’t pay attention to details; makes careless
mistakes”, “Has trouble keeping his/her mind on work or play for long”), conduct disorder (15
items, such as “Bullies, threatens, or scares others”, “Physical hurts people”, “Lies to avoid
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having to do something or get things”, “Steals secretly”) , and Oppositional Defiant Disorder (8
items, such as “Loses temper”, “Argues with adults”, “Is angry and resentful”)71.

The BASC-2 is a comprehensive tool that permits assessment of behavior and emotional
symptoms in children 2-21 yrs of age. The BASC-2 evaluates symptoms of hyperactivity
(engaged in disruptive, impulsive, and uncontrolled behaviors, items e.g. “Cannot wait to take
turn”, “Is unable to slow down”, “Acts without thinking”, “Disruptes other children’s
activities”), aggression (to act aggressively, e.g. “Teases others”, “Bullies others”), conduct
problems (engaged in rule-breaking behavior, such as cheating, deception, and/or stealing),
anxiety (anxiety based behavior, e.g. “Worries”, “Is too serious”), depression (depressive
behavior, e.g. “Is easily upset”, “Complains about being teased”, “Cries easily”), somatization
(complains of health-related problems, e.g. “Expresses fear of getting sick”, “Complains of
pain”, “Has stomach problems”), atypicality (engaged in behaviors that are considered strange or
odd, or disconnected from his surroundings, e.g. “Does strange things” “Acts confused”,
“Babbles to self”), withdrawal (avoid social situations, be capable of developing and maintain
friendships with others, e.g. “Makes friends easily” “Refuses to group activities”), attention
problems (have difficulty maintain necessary levels of attention at school, e.g. “Has a short
attention span”, “Pays attention”), activities of daily living (be able to adequately perform siple
daily tasks, in a safe and efficient manner, e.g. “Has trouble following regular routines”, “Acts in
a safe manner”, “Organizes chores or other tasks well”), adaptability (be able to adapt at variety
of situations, e,g, “Is easily soothed when angry”, “Share toys or possessions with other
children”, ”Recovers quickly after a setback”), functional communication (exhibit adequate
expressive and receptive communication skills, be able to seek and find new information when
needed, e.g. “Provides own telephone number when asked”, “Answers telephone properly”),
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leadership (present a typical level of creativity, ability to work under pressure or team with
others to complete a work assignment, e.g. “Gives good suggestions for solving problems”,
“Joins clubs or social groups”), and social skills (present sufficient social skills and do not
experience debilitating or abnormal social difficulties, e.g. “Congratulates others when good
things happen to them”, “Encourages others to do their best”, “Offers help to other children”).72
Results from BASC-2 provide standard T- scores with mean of 50 and SD of 10, compared to a
large national sample. Combined-sex and separate-sex norms are available.74

When the presence of a clinical syndrome or disorder is of interest, child/adolescent selfreported or parent/teacher reported questionnaires may not be sufficient to distinguish one
syndrome from another. For this purpose a structured diagnostic interview is generally
considered the gold standard.66 Such an interview is conducted by a clinician, often with the aid
of a computer program to generate a decision tree to ask questions in a set / standardized order
and to probe positive responses for clarification. The Diagnostic Interview for Children and
Adolescents (DICA)73 was developed as a semi-structured diagnostic interview for child and
adolescents. DICA is polydiagnositic and can be used for either the DSM-IV or ICD-10, and has
been wildely used in US and Canada.73 It is semi-structured as it provides for opportunities to
deviate from the instrument, especially for younger children and young adults. Respondents are
asked to give examples of the kind of behavior or feelings they have in mind when answering the
questions. Interviewers can be trained lay staff, and do not need to be a clinician to go through
symptoms. Each symptom is rated on its own merit and not in relation to a potential diagnosis,
and then symptoms are combined to generate reliable diagnoses.73
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Parent Emotional Distress/PTSS
Parent emotional distress was assessed using the Brief Symptom Inventory 18 (BSI-18)75
is a self-reported screening inventory designed to assess participants’ level of psychological
distress on three dimensions: depression, anxiety and somatic complaints. The 18 items are
divided equally across the three dimensions and were presented with the standard instructions
asking participants to rate how much they have been “distressed or bothered” in the past 7 days,
including today, by the given symptom, using a 5-point Likert scale ranging from 0 (not at all) to
4 (extremely). Each item contributes to only one subscale, which is scored by summing the
scores on each of the six subscale items. The three raw subscale scores range from 0 to 24.
Parent PTSS was evaluated using the Impact of Event Scale-Revised (IES-R),76 which is a 22item self-report measure which are rated on a 5-point scale ranging from 0 ("not at all") to 4
("extremely"). The levels of stress were calculated for three subscales using symptom raw
scores., thought intrusions (8 items, such as “Any reminder brought back feelings about it.”, “I
had trouble staying asleep.”, “I found myself acting or feeling like I was back at that
time.”),avoidance (8 items, such as “I felt as if it hadn’t happened or wasn’t real.”, “I was aware
that I still had a lot of feelings about it, but I didn’t deal with them.” ), and hyperarousal (6 items,
such as “I felt irritable and angry.”, “I was jumpy and easily startled.”)
Statistical Analysis
For demographic and clinical variables, descriptive statistics were calculated for
continuous variables. Age- and sex-adjusted standard scores were calculated for both self- and
parent-report of child behavioral symptoms, and sex-adjusted standard scores were calculated for
parent self-reported emotional distress. For child symptoms, impairment of Adaptability, Social
Skills, Leadership, Activities of Daily Living, and Functional Communication was defined as

38

≤10th percentile of national normative data (T-score ≤37); impairment of other outcomes were
defined as a score above the 90th percentile compared to normative data (T-score ≥63). For child
mental health conditions, the proportions of children meeting diagnostic criteria on the DICA
were compared to reported frequencies in the 12-month prevalence of DSM-IV disorders in the
National Comorbidity Survey Replication Adolescent Supplement for age of 13-17 years.34 Onesample binomial tests were applied to compare the observed to the expected impairment rate in
the general population. All p-values were adjusted for multiple testing by controlling the false
discovery rate using SAS MULTTEST procedure. Spearman correlation was used to examine
associations between self-reported and parent-reported symptom scores, as well as child’s selfreported anxiety and depression total raw scores with parents’ self-reported anxiety and
depression scores.
Multivariable log-binomial regression analyses were conducted to independently test
associations between each treatment exposure (HDMTX, number of intrathecal therapy doses,
and cumulative dose of dexamethasone) and outcomes of child behavioral symptoms and mental
health conditions, adjusted for age at diagnosis. Similar analyses were conducted to test
associations between parent emotional distress (anxiety, depression and somatization) or the
number of PTSS symptoms reported (avoidance, hyperarousal, and intrusion) with parent- and
self-reported child behavior symptoms, with adjustment for highest parent education. Relative
Risks (RR) and 95% confidence intervals (CI) are reported from all analyses. All analyses were
conducted in SAS 9.4 (SAS Institute, Cary NC).
Results
Demographic, clinical and treatment characteristics of survivors and parents are provided
in Table 8. Fifty-one percent were female, 75% were white, mean age at diagnosis was 4.6
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(Standard Deviation, SD 2.4) years, average follow-up time was 7.5 (SD 1.6) years and 81% of
primary respondents were mothers (Table 8).
Table 8: Demographics and Treatment Characteristics (N=161)
No.

%

Mean (SD)

Median (Min, Max)

Female

82

50.9

Male

79

49.1

White

120

74.5

Others

41

25.5

Age at valuation

Years

161

12.1 (2.6)

11.6 (8.0, 17.9)

Maternal education

Years

158

13.7 (2.5)

13 (6, 20)

Paternal education

Years

153

13.5 (3.1)

12 (0, 22)

Demographics
Gender

Race

Treatment characteristics
Age at diagnosis

Years

161

4.6 (2.4)

3.9 (1.0, 11.9)

Time since diagnosis

Years

161

7.5 (1.6)

7.2 (5.1, 12.0)

Risk Stratum

Low

110

68.3

Standard/High

51

31.7

HDMTX AUC

mg.hr/L

156

30.9 (11.6)

24.2 (19.5, 60.8)

HDMTX cumulative
dose

g/m2

160

15.4 (7.2)

13.5 (6.1,78.8)

Intrathecal therapy a

No. counts

158

14.0 (3.8)

12 (9, 24)

Oral dexamethasone

100 mg/m2

157

11.2 (2.6)

11.0 (2.0, 16.9)

Abbreviations: SD, standard deviation; Min, Max: minimum and maximum values
HDMTX: High dose intravenous methotrexate; AUC area under the curve
a
Triple intrathecal therapy of MTX, hydrocortisone, plus cytarabine.
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Compared to an expected impairment proportion of 10%, a statistically significantly
larger proportion of survivors reported symptoms of inattention, hyperactivity/impulsivity,
learning problems, ADHD hyperactive-impulsive type, ADHD inattentive type, and Oppositional
Defiant Disorder, with impairment proportions ranging from 20-29% (Table 9). Parent report of
survivor symptoms demonstrated statistically significantly higher proportions in the areas of
depression, atypicality, attention problems and activities of daily living (Table 9, range 1726%,). Results from the structured diagnostic interviews with parents demonstrated that
survivors have higher rates of Generalized Anxiety Disorder (3.2 vs. 1.1%, p=0.01), ObsessiveCompulsive Disorder (10.3 vs. 3%, p<0.001) and Oppositional Defiant Disorder (16.0 vs. 8.3%,
p=0.002) compared to rates in the general population of adolescents. The prevalence of ADHD
among survivors (7.1%) was comparable to national normative data (6.5%).
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Table 9: Summary Statistics on Self-Reported and Parent-Reported Behavior Symptoms and
Psychiatric Disorders (N=161)
T-score
Mean (SD)

n (%)

Self-Reported Symptoms/Conditions
Inattention
55.6 (13.9)
Hyperactivity/Impulsivity
55.9 (12.4)
Learning Problems
54.5 (11.3)
Defiance/Aggression
51.1 (11.3)
Family Relations
49.8 (9.5)
ADHD Hyperactive54.9 (12.5)
Impulsive Type
ADHD Inattentive Type
56.1 (13.2)
Conduct Disorder
49.2 (10.4)
Oppositional Defiant
53.1 (11.8)
Disorder
Parent-Reported Symptoms
Hyperactivity
50.4 (12.7)
Aggression
48.2 (10.1)
Conduct Problems
48.7 (10.9)
Anxiety
50.4 (12.4)
Depression
51.2 (12.0)
Somatization
50.9 (12.3)
Atypicality
50.5 (11.3)
Withdrawal
48.9 (10.3)
Attention Problems
53.3 (11.3)
Adaptability
50.5 (10.3)
Social Skills
48.8 (10.0)
Leadership
48.7 (10.1)
Activities of Daily Living
45.9 (10.6)
Functional
48.8 (9.9)
Communication
Parent-Reported Psychiatric Disorders
Expected a
(%)
ADHD Present
6.5
Conduct Disorder b
5.4
Major Depressive disorder
8.2
or Dysthymic
Generalized Anxiety
1.1
Disorder
Obsessive-Compulsive
3
Disorder
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Impairment
Exact 95%
CL

P

43 (27.9)
40 (26.0)
35 (22.7)
18 (11.7)
17 (11.0)
38 (24.7)

21.0-35.7
19.2-33.6
16.4-30.2
7.1-17.8
6.6-17.1
18.1-32.3

<0.0001
<0.0001
<0.0001
0.62
0.75
<0.0001

45 (29.2)
16 (10.4)
31 (20.1)

22.2-37.1
6.1-16.3
14.1-27.3

<0.0001
0.87
0.00004

24 (15.3)
13 (8.3)
14 (9.0)
20 (12.7)
26 (16.6)
24 (15.3)
28 (17.9)
17 (10.8)
37 (23.6)
18 (11.5)
24 (15.3)
23 (14.7)
40 (25.5)
21 (13.5)

10.0-21.9
4.5-13.7
5.0-14.6
8.0-19.0
11.1-23.3
10.0-21.9
12.3-24.9
6.4-16.8
17.2-31.0
6.9-17.5
10.0-21.9
9.6-21.3
18.9-33.0
8.5-19.8

0.054
0.60
0.72
0.35
0.022
0.054
0.004
0.73
<0.0001
0.63
0.054
0.084
<0.0001
0.23

n (%)

P

11 (7.1)
1 (0.6)
7 (4.5)

Exact 95%
CL
3.6-12.3
0.0- 3.5
1.8- 9.0

0.78
0.03
0.11

5 (3.2)

1.0- 7.3

0.03

16 (10.3)

6.0-16.2

<0.0001

Table 9: (Continued). Summary Statistics on Self-Reported and Parent-Reported Behavior
Symptoms and Psychiatric Disorders (N=161)

Expected
(%)
Parent-Reported Psychiatric Disorders
Oppositional-Defiant
8.3
Disorder
Panic Disorder
1.9

Impairment
n (%)

a

Exact 95%
CL

P

25 (16.0)

10.6-22.7

0.002

0 (0.0)

0.0- 2.3

0.11

T-score: Age- and Sex adjusted T scores, mean=50, SD=10; Impairment for Adaptability, Social
Skills, Leadership, Activities of Daily Living, and Functional Communication impairment was
defined as ≤10th percentile of national norm (T-score ≤37); for other variables, impairment was
defined as ≥90th of national normative data (T-score ≥63).
Expected a: prevalence estimate of DSM-IV disorders among US adolescents, Kessler RC et al,
2012;
P: p-value for two-sided, one sample Binomial test for p=0.1 with False Discovery Rate
adjustment.
Conduct Disorder b: Frequency of impairment is lower than national normative data.

Parent emotional distress and PTSS outcomes were also comparable to national
normative data (Table 10). Chemotherapy treatment was not associated with any of the child and
parent outcomes (Table 11).
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Table 10. Summary Statistics for Parent Emotional Distress and Post-traumatic Stress Outcomes
n
†

Mean (SD)

Emotional Distress
Anxiety
155
45.7 (9.6)
Depression
155
44.7 ( 7.3)
Somatization
155
44.9 ( 6.7)
Post-traumatic Stress Symptoms ‡
Avoidance
153
5.6 ( 6.0)
Hyperarousal
153
3.8 ( 5.2)
Intrusion
153
2.4 ( 3.9)
Abbreviations: SD, standard deviation
† Brief Symptom Inventory 18 (BSI-18): sex-adjusted T scores (mean=50, SD=10)
‡ Impact of Event Scale-Revised (IES-R): number of symptoms reported
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Table 11. Association of Chemotherapy Treatment Effect and Child and Parent Outcomes
Intrathecal therapy †

HDMTX AUC
Survivor Outcomes

Oral dexamethasone

‡

RR
95% CI
Self-Reported Symptoms
Inattention
0.98
0.96- 1.01
Hyperactivity/Impulsivity 1.01
0.99- 1.03
Learning Problems
1.01
0.99- 1.04
ADHD Hyperactive1.01
0.99- 1.03
Impulsive Type
ADHD Inattentive Type
0.99
0.97- 1.02
Oppositional Defiant
0.99
0.96- 1.02
Disorder
Parent-Reported Symptoms
Depression
1
0.97- 1.03
Atypicality
0.99
0.96- 1.03
Attention Problems
1
0.98- 1.03
Activities of Daily Living 0.98
0.95- 1.01
Parent-Reported Psychiatric Disorders
Generalized Anxiety
1
0.94- 1.06
Disorder
Obsessive-Compulsive
1.03
0.99- 1.06
Disorder
Oppositional-Defiant
0.98
0.94- 1.01
Disorder
Parent Outcomes §
Est
SE
Emotional Distress
Anxiety
0.027 0.014
Depression
0.011 0.01
Somatization
0.006 0.01

P

RR

95% CI

P

RR

95% CI

P

0.465
0.465
0.465
0.465

0.96
1.02
1.05
1.04

0.89- 1.03
0.96- 1.09
0.98- 1.12
0.97- 1.11

0.56
0.71
0.56
0.56

0.92
0.99
1.07
1.02

0.85- 1.00
0.89- 1.11
0.94- 1.21
0.91- 1.15

0.18
0.89
0.64
0.89

0.53
0.53

0.99
1.02

0.92- 1.06
0.94- 1.10

0.71
0.71

0.91
0.98

0.84- 0.99
0.86- 1.13

0.12
0.89

0.91
0.91
0.91
0.6

1.01
1.04
1
0.98

0.93- 1.08
0.97- 1.12
0.94- 1.07
0.92- 1.05

0.92
0.92
0.92
0.92

1.02
1
0.95
0.99

0.89- 1.17
0.87- 1.16
0.85- 1.06
0.89- 1.10

0.95
0.95
0.95
0.95

0.95

0.84

0.63- 1.12

0.63

0.93

0.67- 1.28

0.66

0.3

1.04

0.94- 1.16

0.63

1.18

0.95- 1.47

0.39

0.3

0.99

0.91- 1.08

0.84

0.94

0.81- 1.09

0.6

P

Est

SE

P

Est

SE

P

0.14
0.41
0.55

0.051
0.042
-0.003

0.041
0.031
0.029

0.33
0.33
0.92

0.046
0.025
0.019

0.06
0.046
0.043

0.66
0.66
0.66
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Table 11. Association of Chemotherapy Treatment Effect and Child and Parent Outcomes (continued)
Intrathecal therapy †

HDMTX AUC
Survivor Outcomes

Oral dexamethasone

‡

Post-traumatic Stress
Symptoms
Avoidance
Hyperarousal
Intrusion

RR

95% CI

P

RR

95% CI

P

RR

95% CI

P

0.074
0.027
0.031

0.037
0.028
0.043

0.14
0.48
0.48

0.153
0.064
0.022

0.112
0.085
0.13

0.51
0.69
0.86

0.09
0.071
0.012

0.166
0.124
0.191

0.89
0.89
0.95

Abbreviations: RR, Relative Risk; 95% CI, 95% Confidence Interval; Est, Parameter Estimate; SE, Standard Error; HDMTX AUC,
high dose IV methotrexate plasma concentration (area under curve [AUC]); † Triple intrathecal therapy of MTX, hydrocortisone, plus
cytarabine oral dexamethasone, oral dexamethasone cumulative dose per 100 mg/m2 at 120 week.P: P-value from multiple regression
analysis adjust for age at diagnosis, with FDR adjustment. ‡ Relative Risk per 1 unit of HDMTX AUC increased, or 1 more intrathecal
injection, or 100 mg/m2 increase in oral dexamethasone. §BSI T-score or number of PTS symptoms per 1 unit of HDMTX AUC
increased, or 1 intrathecal injection increased, or 100 mg/m2 increase in oral dexamethasone.
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Survivors’ self-report of inattention, hyperactivity/impulsivity, and defiance/aggression
symptoms was significantly correlated with parent report of child attention problems,
hyperactivity, and aggression/conduct problems, respectively, with all pairwise Spearman
correlation coefficients ranging from 0.32 to 0.44 and all p-values<0.001 (Table 12a). However,
survivors’ self-reported anxiety (r=0.25, p=0.002) and depression (r=0.17, p=0.04) symptoms
were weakly correlated with parent report of these survivor symptoms. Survivors’ self-reported
symptoms of mental health conditions (i.e., ADHD hyperactive-impulsive type, ADHD
inattentive type, Conduct Disorder and Oppositional Defiant Disorder) were statistically
significantly associated with parent report of survivor mental health disorder (Table 12b).
Although parents identified a significant proportion of survivors with Generalized Anxiety
Disorder and Obsessive Compulsive Disorder, psychiatric disorders associated with significant
anxiety,34,67 these conditions were not associated with survivors’ self-report of anxiety symptoms
(Figure 5).

The majority of parents did not self-report elevated symptoms of emotional distress or
PTSS (Table 10). Parent self-reported anxiety and depression were associated with an 18-67%
higher risk for parent report of survivor anxiety, atypicality, Generalized Anxiety Disorder and
Obsessive-Compulsive Disorder (Figure 6). Parent self-reported PTSS was also associated with
parent report of survivor anxiety, somatization, atypicality, withdraw, Generalized Anxiety
Disorder and Obsessive-Compulsive Disorder (Figure 7).
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Table 12a: Association of Self- Reported and Parent-Reported Child’s Behavior Symptoms
Survivor-Reported Symptoms
Inattention †
Hyperactivity/
Impulsivity†

Learning Problems†

Parent-Reported
Symptoms †
Hyperactivity
Aggression
Conduct Problems

r (p)

r (p)

r (p)

r (p)

0.31 (<0.0001)
0.31 (<0.0001)
0.31 (<0.0001)

0.41 (<0.0001)
0.30 (<0.0001)
0.35 (<0.0001)

0.26 (0.002)
0.15 (0.063)
0.17 (0.042)

0.34 (<0.0001)

Anxiety
Depression
Somatization
Atypicality
Withdrawal
Attention Problems

0.12 (0.145)
0.32 (<0.0001)
0.08 (0.324)
0.31 (<0.0001)
0.21 (0.010)

0.10 (0.222)
0.20 (0.015)
-0.02 (0.772)
0.24 (0.004)
0.08 (0.324)
0.35 (<0.0001)

0.15 (0.070)
0.24 (0.003)
0.04 (0.622)
0.19 (0.018)
0.09 (0.256)
0.34 (<0.0001)

0.32 (<0.0001)
0.41 (<0.0001)
0.01 (0.856)
0.24 (0.004)
0.01 (0.913)
0.32 (<0.0001)
0.20 (0.014)
0.31 (<0.0001)

-0.25 (0.002)
-0.13 (0.119)
-0.19 (0.019)
-0.26 (0.002)

-0.16 (0.045)
-0.01 (0.863)
-0.21 (0.009)
-0.27 (0.001)

-0.21 (0.010)

-0.29 (<0.0001)

Adaptability
Social Skills
Leadership
Activities of Daily
Living
Functional
Communication

0.44 (<0.0001)
-0.26 (0.002)
-0.17 (0.041)
-0.26 (0.001)
-0.33 (<0.0001)
-0.27 (0.001)

Defiance/ Aggression†

Anxiety ‡

Depression ‡

r (p)

r (p)

r (p)

0.25 (0.002)
0.20 (0.016)
0.30 (<0.0001)

0.19 (0.020)
0.13 (0.124)
0.21 (0.010)

0.19 (0.022)
0.12 (0.145)
0.23 (0.005)

-0.09 (0.270)
0.14 (0.096)
-0.03 (0.698)
0.24 (0.003)
0.10 (0.222)
0.32 (<0.0001)

0.25 (0.002)
0.26 (0.001)
0.18 (0.023)
0.24 (0.004)
0.19 (0.018)
0.25 (0.002)

-0.10 (0.217)

-0.38 (<0.0001)
-0.25 (0.002)
-0.33 (<0.0001)
-0.31 (<0.0001)

-0.23 (0.004)
-0.18 (0.029)
-0.16 (0.047)
-0.30 (<0.0001)

-0.25 (0.002)
-0.08 (0.354)
-0.12 (0.155)
-0.15 (0.065)

-0.12 (0.125)
-0.09 (0.279)
-0.16 (0.052)
-0.22 (0.006)

-0.30 (<0.0001)

-0.24 (0.003)

-0.18 (0.029)

-0.16 (0.055)

Family Relations
†

0.17 (0.037)
0.01 (0.870)
0.17 (0.041)
0.10 (0.232)
0.26 (0.001)

Abbreviations: r (p), Spearman Correlation Coefficient (p-value);
†
Age- and Sex-adjusted T scores (Mean=50, SD=10); ‡ Symptom raw scores; § Impaired Symptom (T-score ≥63);
Note: r (p) with bold fonts in the top part of the table indicate the suggested the outcomes with same measures between self and parent
reports.
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Table 12b. Association of Self- Reported and Parent-Reported Child’s Psychiatric Disorders
Self-Reported Symptoms of Conditions
ADHD HyperactiveADHD Inattentive
Conduct Disorder § Oppositional
§
§
Impulsive Type
Type
Defiant Disorder §
RR (95% CI)
RR (95% CI)
RR (95% CI)
RR (95% CI)
Parent-Reported Disorders¶
ADHD
5.05 ( 1.27-20.10 )
4.11 ( 1.03-16.44 )
4.99 ( 1.31-18.94 )
3.81 ( 1.01-14.37 )
Generalized Anxiety Disorder
1.01 ( 0.11- 9.41 )
0.82 ( 0.09- 7.68 )
1.27 ( 0.14-11.78 )
8.31 ( 1.26-55.03 )
Obsessive-Compulsive Disorder 2.25 ( 0.84- 6.06 )
1.36 ( 0.48- 3.82 )
1.57 ( 0.53- 4.67 )
3.30 ( 1.17- 9.31 )
Oppositional Defiant Disorder
1.51 ( 0.66- 3.46 )
1.85 ( 0.84- 4.07 )
3.32 ( 1.51- 7.34 )
2.85 ( 1.32- 6.16 )
Abbreviations: RR, Relative Risk; 95% CI, 95% Confidence Interval. ADHD, Attention-Deficit/Hyperactivity Disorder
§
Impaired Symptom (T-score ≥63); ¶ Child psychiatric disorders meeting clinical criteria.
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Figure 5. Association between Self-Reported Anxiety Raw Score and Parent-Reported Child
Anxiety Disorders. Box and Whisker plot: Self-reported anxiety raw score (Mean and 95% CI)
vs. parent-reported child Obsessive-Compulsive Disorder and Generalized Anxiety Disorder.

50

Figure 6. Relative Risk for Parent Emotional Distress on Self- and Parent- Reported Behavior Symptoms and Psychiatric Disorders.
Multiple regression analysis adjusted for parents' highest education level in years; Relative Risk and 95% Confidence Interval scale:
per 0.5 SD of Parent Emotional Distress BSI T-score increased.
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Figure 7. Relative Risk and 95% Confidence Interval for Parent Posttraumatic Stress Symptoms on Self- and Parent-Reported
Behavior Symptoms.
Multiple regression analysis adjusted for parents' highest years of education. Relative Risk and 95% Confidence Interval scale: per one
more symptom reported according to Event Scale-Revised.
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Discussion
In the current study of child and adolescent long-term survivors of childhood ALL treated
on a contemporary chemotherapy-only protocol, a significantly higher prevalence of behavioral
inattention problems was reported by both survivors and parents compared to national normative
data. In contrast, the prevalence of ADHD, based on a structured diagnostic interview, did not
differ from the general population. Survivors also reported a significantly higher frequency of
learning problems, which may be associated with behavioral inattention problems. Compared to
national normative data, survivors reported significantly more symptoms of oppositional
behavior and this behavior was consistent with Oppositional Defiant Disorder ascertained from
structured diagnostic interviews with parents. Parents identified increased prevalence of
Generalized Anxiety Disorder and Obsessive-Compulsive Disorder in survivors relative to
national data; however, these conditions were more strongly associated with parents’ selfreported distress than with the survivors’ self-reported anxiety.
Agreement was demonstrated between diagnosis of Oppositional Defiant Disorder based
on structured diagnostic interview, and survivors’ report of symptoms of Oppositional Defiant
Disorder. This disorder is characterized by children showing a persistent pattern of anger and
irritable mood or argumentative and defiant behavior towards authority figures such as parents or
teachers.67 As one of the most commonly diagnosed psychiatric disorders in childhood and
adolescence, the behavior can negatively impact children’s social, academic or educational
functioning.77 Family functioning plays an important role for a stable parent-child relationship.
Previous research has shown that almost half of adolescent survivors, as well as a third of fathers
and a quarter of mothers, report poor family functioning,78 which may reflect parent-child
conflict. Other studies show family conflict during cancer treatment, but suggest long-term
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family resilience.79 Attention and executive functions such as working memory, cognitive
flexibility and organization skills are important for children to comply with parental demands.
Deficits in these skills may contribute to negative interaction with parents and lead to a pattern of
defiant behaviors.77 Long-term childhood ALL survivors with chemotherapy only treatment
show eight times higher frequency of severe impairment in executive function compared to the
general population.7 Impaired executive function has been shown to be associated with
emotional/behavioral outcomes among adolescent survivors of childhood ALL,80 which may
help explain the high prevalence of Oppositional Defiant Disorder in this population.
Interventions targeted Oppositional Defiant Disorder may need to be modified to take into
account the neurocognitive functioning of survivors.
Survivor-report of symptoms of inattention was consistent with parent-report of survivor
attention problems. Attention problems have been reported in a large cohort of adult survivor of
ALL.7 In that study, long-term survivors treated with chemotherapy only demonstrated
significantly worse performance on direct testing of sustained attention compared to normative
data.46 Long-term survivors of childhood ALL have also been reported to demonstrate significant
difficulty in inhibitory control,81 that may contribute to the reported problems with
hyperactivity/impulsivity in the current study. Childhood Cancer Survivor Study investigators
observed that parents reported a higher frequency of inattention/hyperactivity among adolescent
survivors of ALL survivors compared to siblings.29 Although more attention problems were
noted in the current cohort, the rate of clinical diagnosis of ADHD was similar to the general
population, thus the attention deficits likely reflect neurocognitive and learning problems rather
than a pattern consistent with developmental ADHD.42,82
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Parent report of Generalized Anxiety Disorder and Obsessive-Compulsive Disorder was
higher than expected based on population data. Interestingly, the presence of the disorders
identified by parents was not associated with survivors’ self-report of anxiety. Instead, it was
associated with parent self-report of emotional distress and PTSS. Survivors may develop
mannerisms (e.g. germs avoidance) response to their previous disease. Previous studies have
observed that parents of childhood cancer survivors experience higher psychological distress
compared to the general population.68 Maternal self-reported anxiety, stress, and depression have
been identified to impact parent-report of child emotional and behavior problems in the general
non-cancer population.83 Parents’ emotional distress may promote a negative bias towards
perceiving behavioral and emotional problems in their children. In addition, there is a strong
behavioral modeling component to anxiety. That is, parents may engage in anxiety related
behaviors (avoidance, obsessions) and model these for their children who thus become more
likely to demonstrate the behaviors.
We did not find associations between chemotherapy treatment and any child self- or
parent-reported symptoms or psychiatric disorders. In a study from the Children’s Cancer Group
(CCG protocol 105), parents and teachers reported child behavioral problems and social function
in long-term survivors of ALL, and problems were not associated with intensive chemotherapy
regimens.84 A study of behavioral outcomes in long-term survivors of childhood ALL from the
Netherlands also demonstrated no associations between chemotherapy intensity and behavior
problems rated by parents.85 A lack of association between chemotherapy treatment and a child’s
behavior symptoms and psychiatric disorders suggests that the cancer experience (e.g., recurrent
hospitalizations, painful procedures) and not the treatment itself may contribute to the
development of the behavioral and emotional problems.86,87
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This study should be viewed in light of several limitations. First, there was no healthy
control group included in this study. However, we have a relatively large sample of childhood
ALL survivors, self- and parent-reported behavior symptoms were evaluated using two widely
used rating scales,67 and T-scores were generated from national normative data with age- and
sex- adjustment, which to some extent, mitigates the concern of not having a healthy control
group. Second, psychiatric diagnoses in the current study were determined with the DICA and
referred to the 12-month prevalence from the National Comorbidity Survey which used the
Composite International Diagnostic Interview (CIDI). Our study used a slightly different
measure, the DICA, which is a validated semi-structured interview. The DICA and CIDI are
structured diagnostic interviews that produce comparable results.34 Third, there was no pretherapy testing of behavior symptoms or diagnosis, but such assessments are difficult to obtain in
young children at the time of a cancer diagnosis. To account for this limitation, we adjusted
analyses for parent education, which should provide a reasonable surrogate for socioeconomic
status.62 Last, this is a single center study, potentially limiting generalization. Patients receiving
treatment and survivorship care at St. Jude, have strong social and psychological support,
therefore the prevalence of symptoms and disorders among patients may be reduced compared to
clinics without such support.
In summary, a significant minority appear to exhibit significant symptoms of inattention
and oppositional behavior based on agreement between child and parent report. Treatment
exposures are not associated with these symptoms as reported in other studies, which suggest
that the cancer experience itself may play a major role in the development of these symptoms
and disorders. Further, parental emotional status appears to influence perception and reporting of
child outcomes. Our findings suggest that preventative intervention targeting behavioral
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outcomes in pediatric patients with ALL and, when present, emotional distress in parents should
be considered.
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Chapter 4
FEASIBILITY AND EFFICACY OF TRANSCRANIAL DIRECT CORRENT STIMULATION
(TDCS) AND CONITIVE TRAINING FOR EXECUTIVE DYSFUNCTION IN ADULT
SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEINA (ALLSTIM): A
PHASE II STUDY
Introduction
Long-term survivors of childhood ALL suffer from neurocognitive impairments,
particularly in executive function and attention,7,15 which have a negative impact on their
educational attainment29,88, employment29,88, health behaviors29,89, quality of life90 and social
functioning.88,91 We have recently identified that higher treatment intensity, as reflected through
serum concentration of methotrexate (MTX), is associated with lower executive function and
related brain imaging outcomes.46 Specifically, higher treatment intensity was associated with
higher functional magnetic resonance imaging activity in dorsolateral frontal brain regions
during equivalent performance on an executive function/attention task. This finding suggests that
frontal brain regions may be functioning less efficiently in survivors treated with more intense
therapy than those treated with less intensive therapy. Research efforts need to be directed on
improving efficiency of brain and neurocognitive functions in these regions.
Compared to the number of recent studies characterizing neurocognitive outcomes in
survivors of ALL, relatively limited research has focused on developing interventions for
improving late-effects.92-96 Many interventions for improving cognitive functions have been
conducted in the general and aging populations, as well as in patients with neuropsychiatric
diseases. These interventions include cognitive training97, physical exercises98,99 and use of
pharmacological agents such as methylphenidate and modafinil.100,101 Physical activity training
promotes a general increase in cerebral blood flow and brain volume for gray matter and white
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matter, which has been associated with improved general brain health.102-104 Cognitive training is
intended to strengthen neural networks through repetitive activation, with the goal of improving
efficiency.105 Pharmacological agents act to enhance specific or multiple functions by either
stimulating neurotransmitter release, or blocking reuptake, both of which can produce undesired
side effects.106
A recently developed technique for cognitive enhancement is transcranial Electrical
Stimulation (tES) which includes transcranial Direct Current Stimulation (tDCS), transcranial
alternating stimulation (tACS) and transcranial random noise stimulation (tRNS) 107-110. tES
adopts a different mechanism of cognitive enhancement from conventional interventions; it
directly stimulates brain regions responsible for the cognitive process and activates functional
networks similar to those activated during cognitive training.110 It is thought that the underlying
neurophysiological mechanisms of tES may overlap with cognitive training, thus the
combination of tES with cognitive training may lead to synergistic effects and maximize
cognitive enhancement.110 For example, studies have found that the combination of cognitive
training with stimulation in the parietal brain region results in improvement in cognitive function
such as number discrimination, and these improvements are maintained for at least 16 weeks.
Training without electrical simulation did not show the maintenance of learning over the
extended period of time.111
Transcranial direct current stimulation (tDCS) is currently the most widely used and
studied technique for tES.110 tDCS involves modulation of cerebral cortex excitability by the
direct application of electrical current. A weak current of < 0.10 C/cm2 is presented at an anode
electrode site and the current travels to a cathode electrode site, stimulating brain regions that lie
in the path of the current flow.
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The impact of tDCS on improving cognitive domains of working memory, short-term and
long-term memory, as well as speech and language has been previously studied among healthy
volunteers and neuropsychiatric patients.110 A systematic review and meta-analysis demonstrated
mixed results on cognitive tasks (e.g. working memory) by stimulation with anode tDCS at the
dorsolateral prefrontal cortex (DLPFC) compared to sham treatment. Results suggested that after
stimulation (offline), reaction time but not accuracy was significantly improved in healthy
participants but not in neuropsychiatric patients, while accuracy was significantly improved
during tDCS stimulation (online) in neuropsychiatric patients.107,108,112 A recent study was
conducted by combining tDCS and cognitive training on n-back working memory (WM) task
(the participant is presented with a sequence of stimuli, and the task consists of indicating when
the current stimulus matches the one from n steps earlier in the sequence.) among 20 healthy
participants and showed that tDCS enhanced skill acquisition from cognitive training.113
Neuroimaging studies have shown that during the n-back task, dorsolateral and ventrolateral
prefrontal cortex and other brain regions are consistently activated.114
tDCS is a safe method for enhancing cortical responsiveness. As stated above, a weak
current of <0.10 C/cm2 is typically used during stimulation. As a reference, tissue damage occurs
at levels of ~ 200 C/cm2 or higher. A meta-analysis115 evaluated over 200 studies for adverse
events (AE) related to active tDCS, and found 56% of studies reported mild AEs. The most
common AE’s reported were itching, tingling, mild headache, and discomfort, however, none of
the AE’s differed in frequency between the placebo (sham application) and active treatment
groups. No studies have documented serious AEs that require urgent medical interventions. A
dose of 2mA of current over 5-20 minutes for 1-10 days has been used in various studies without
significant adverse events. A recent meta-analysis showed that participant drop-out rate due to
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AEs was similar in the active tDCS group (6%) vs. sham group (7.2%), and that tDCS
acceptability by patients did not differ in studies with different current dose levels (<2 vs.
2mA).116
Clinical studies have also demonstrated the efficacy of tDCS intervention among patients
suffering from stroke,117 depression,118,119 psychosis, and Alzheimer’s disease120. However, the
feasibility and efficacy of tDCS in improving neurocognitive function of long-term adult
survivors of childhood cancer has not been evaluated. Since these adults likely experienced
neurocognitive impairments when they were treated many years ago, the potential benefit to
them may differ from those with active disease processes. We thus conducted a phase II study to
assess the feasibility and potential efficacy of a 5-week tDCS intervention paired with cognitive
training in improving executive function in long-term adult survivors of childhood ALL.
Stimulation and training were to be conducted at home twice weekly for five weeks. Prior to
initiating the home trial, we conducted a 2-day trial in the clinic to evaluate the short-term effect
of tDCS on measures of executive function. This clinic-based trial also provided participants
with an on-sight experience with tDCS under direct supervision before they self-administered the
home-based intervention remotely.
Objectives of the study
The primary objective of the pilot study is to evaluate the feasibility of a home-based
intervention using tDCS and cognitive stimulation in adult survivors of childhood ALL.121 The
secondary objectives are to (1) to explore the short-term effect of tDCS on measures of executive
function among adult survivors of childhood ALL, and (2) to estimate the efficacy of a remotely
administered tDCS intervention paired with cognitive training.
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Methods
Research Participant Eligibility Criteria and Study Enrollment
This study was approved by the institutional review board at St. Jude Children’s Research
Hospital, and informed consent/assent were obtained from all participants. The inclusion criteria
were: (1) current participant in the St. Jude Lifetime Cohort study; (2) long term survivor of
acute lymphoblastic leukemia (ALL); (3) currently ≥ 18 years of age; (4) Wi-Fi internet access at
home (>75% of the SJLIFE cohort); (5) history of executive dysfunction, documented by
previous SJLIFE neurocognitive testing, and defined as having an age-adjusted standard score
<10th percentile on Trail Making Test Part B,122 Verbal Fluency122, or Digit Span Backward123;
and (6) able to speak and understand the English language. The exclusion criteria were: (1)
survivors with full scale IQ <80; (2) currently on stimulants or other medications intended to
treat cognitive impairment; (3) history of seizures; (4) implanted medical devices or implanted
metal in the head; (5) currently pregnant or planning to become pregnant; (6) inability or
unwillingness of research participant or legal guardian/representative to give written informed
consent. The off-study criteria included: (1) all protocol interventions are complete; (2) request
of participant/legally authorized representative; (3) death; (4) lost to follow-up; and (5) discretion
of the study PI (e.g. the researcher decides that continuing in the study would be harmful, or
other treatment is needed that is not allowed on this study).
Design and Study Overview
The study was conducted in two parts. In Part I, the short-term effect of tDCS on
performance on measures of executive function were evaluated over a two-day period. After
assessing the effectiveness in Part I, the feasibility of self-administering tDCS over long-term (5
weeks with two sessions per week) using a mobile tDCS device and its potential efficacy were
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evaluated in Part II. The 5-week intervention was paired with cognitive stimulation using the
Lumosity Brain Games program (www.lumosity.com). This program involves cognitive
exercises designed to enhance executive function, attention and processing speed, which takes
about 15 minutes. Cognitive stimulation activities can be completed in 15-20 minutes per
session, and were administered on an institutionally provided iPad. The study schema is
displayed in the Figure 8.

Figure 8. ALLSTIM Study Schema
A cross-over randomized trial was used in Part I. The survivors were randomized to
receive either the tDCS intervention at the current dose level of 2mA or Sham for 15 minutes on
day 1 and then on day 2 the treatment was switched (i.e. those who got tDCS intervention of day
1 got sham on day 2 and vice versa). The tDCS intervention was delivered by the Soterix
Transcranial Direct Current Stimulator Clinical Trials (1x1-CT). The effect of one session to
tDCS was expected to last for about two hours thus conducting the second session the next day
provided sufficient time for the “wash-out” and good justification for using a cross-over design.
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In Part II, the feasibility and efficacy of 5 weeks of self-administration of the tDCS (1
mA, 15 minutes) intervention in concurrence with self-administered cognitive training was
evaluated. In this part, the research participants were taught to use the mobile tDCS device and
were provided with one to take home. The device was programmed by the investigators in
advance to control the intensity and duration of the stimulation. The research participants were to
use the device twice per week as directed. Before each session, the participants used an
institutionally provided iPad for video conferencing with the study center to obtain a unique
access code to start the tDCS device and ensure proper device placement. Each stimulation
session for each participant had a unique access code. Research participants also completed
remote neurocognitive testing via the iPad before and after Part II.
Adverse Event (AE) Monitoring
Adverse events were surveyed by a trained study team member before and after
stimulation at both onsite clinic visits (Part I) and the remote session (Part II). For the
remote session, AE were surveyed at the beginning of each video conference with
symptoms reports for the prior stimulation session. Adverse event information was
collected f r o m participants w i t h direct questioning using a modified patient report of
incidence of side effects (PRISE) for categories specific to the possible side effects of the
device (Skin, Nervous System, Eyes/Ears, Sleep, Other). If a participant indicated the
presence of a side effect, then the frequency and intensity (severity) of that side effect were
captured using frequency and intensity of side effect rating (FISER) and global rating of
side effects burden (GRSEB). The FISER and GRSEB assess three domains of side
effect impact: frequency, intensity (severity), and burden. Each domain is rated on a 7point Likert scale (i.e. Frequency, ranging from no side effects to present all the time;
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Intensity (severity), ranging from no side effects to intolerable; and Burden, ranging
from no impairment to unable to function due to side effects).
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Neurocognitive Evaluations
Pre-Study Evaluations
All participants in SJLIFE undergo neurocognitive testing as part of the SJLIFE parent
protocol. The Digit Span Backwards, Trial B Making Test, and Verbal Fluency Test scores were
used to identify survivors eligible for our study (i.e. Score of any test <20th percentile compared
to normative data).
Evaluation during Part I
Neurocognitive tests were completed after active and sham stimulation during Part I.
Executive function measures included three tests from the Cognitive Battery of the NIH
Toolbox124 which have shown excellent test-retest reliability.125,126 Testing included (1)
Dimensional Change Card Sort Test (DCCS) for cognitive flexibility (test-retest reliability
Intra-class correlation coefficient, ICC=0.81, 95% CI 0.72-0.87)125, (2) Flanker Inhibitory
Control and Attention Test for inhibitory control and attention (test-retest reliability
ICC=0.83, 95% CI 0.74-0.89)125, and (3) List Sorting Working Memory Test for
information processing and storage or working memory (test-retest reliability ICC=0.77,
95% CI 0.67-0.84).126
We also completed measures of reading and listening comprehension, including the Gray
Oral Reading Test (GORT-4, ICC>0.9)127 to measure reading comprehension. Responses to the
test required literal as well as inferential comprehension. Two stories were given each day, one
day from Form A and one day from Form B. Raw scores were calculated for total accuracy, and
compared within participants.

The Woodcock Johnson Understanding Directions test was used

to measure listening comprehension (ICC=0.83)128, which requires sequential and logical
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reasoning. The task required the participant to listen to a series of complex instructions and
then followed the directions by pointing to various objects in a colored picture.
Remote Assessment Procedures
We conducted neurocognitive testing via video conferencing with the iPad prior to the
first stimulation session and following the last stimulation session of Part II of the trial. At a
scheduled time, an examiner contacted the participant and administered the following tests: (1)
Digit Span subtest from the Wechsler Adult Intelligence Scale129(2) Verbal fluency (ICC=0.80)
from the Delis-Kaplan Executive Function System122; (3) Oral trail making test; and (4) CCSS
Neurocognitive Questionnaire130. For the Digit span test, the examiner read a series of number
sequences to the participant, and the participant was required to repeat the number sequence in
the same order (Digits Forward; a measure of memory span, ICC=0.77) 129 or in reverse order
(Digits Backward; a measure of working memory, ICC=0.71) 129. During the verbal fluency test
the examiner said a letter of the alphabet, and the participant was required to state as many words
as s/he could that begin with the specified letter within 60 seconds; with a total of three letters
are given. The oral trail making test requires the participant to count from 1 to 25 as quickly as
possible (focused attention), and then switched between sequentially stating numbers and letters
(i.e. “1, A, 2, B, 3, C…”; a measure of cognitive flexibility). Participants were also required to
respond to the CCSS Neurocognitive Questionnaire130 to report the frequency of cognitive
problems they may have experienced. Four neurocognitive domains were evaluated in the
questionnaire: Task Efficiency (initiating and completing tasks in a rapid manner); Emotional
Regulation (emotional reactivity and frustration tolerance); Organization (organization of the
individual’s environment); and Memory (working memory and long-term memory).
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Statistical Consideration
Design

The entire trial would be considered to be unacceptable based on toxicity if at any time
point at least five patients (≥5) had grade three or higher adverse events.
Feasibility: The primary focus of our study was to assess if the administration of tDCS treatment
remotely would be feasible, i.e. Part II of the trial. A survivor would be considered to have
completed the study if they were able to complete at least five out of 10 sessions (tDCS along
with cognitive stimulations). Part II of the study was considered to be feasible if at least 50% of
the survivors completed the study. The feasibility of the study was evaluated using Simon’s twostage Minimax design for testing the hypothesis H0:P≤0.5 vs. H1:P1>0.7 with type I error rate
=0.05 and power (1-)=0.8 with the following stopping rules. In the first stage, we were to
recruit 23 survivors and at least 13 survivors would need to complete the study. Then we would
proceed to the next stage and recruit an additional 14 survivors. If at least 24 survivors out of 37
completed the study then the tDCS trial would be considered feasible. With an expected drop-out
rate of roughly 10% (survivors who may not initiate the trial after leaving the institution) we
planned to enroll a total of 42 survivors for the evaluation of feasibility of the study.
Statistical Analysis
For the primary objective, the feasibility of the 5-week tDCS intervention was evaluated
using Simon's two stage Minimax design with stopping rules described above. For two
secondary objectives on efficacy on clinic visit (Part I of the trial), the contrast in the scores on
the NIH Toolbox Card Sort, Flanker and Working Memory tasks, as well as Gary Oral Reading
Test and Woodcock Johnson Understanding Directions between tDCS and sham for each
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participant were obtained and tested using one sample t-test on the difference of the paired
measurements. The potential effect of the order of tDCS was evaluated using one sample t-test
on difference of two measurement between two days. For remote sessions (Part II of the trial),
the change in scores on Digit Span Test, verbal fluency, Oral Trail Making Test and NCQ
Executive function measures from baseline to 5-week follow up for remote session were
obtained and tested using one sample t-tests. In addition, the impact of cranial radiation effect on
the change in the outcomes was explored using general linear models (GLM), with the
adjustment of survivor’s age at diagnosis, year of follow-up, sex and the outcome measures at
baseline (before the stimulation). Statistical Significance was set to 0.05. All analyses were
conducted using SAS 9.4 (SAS Institute, Cary NC).
Results
A total of 36 research participants were recruited for the study and completed on campus
clinic visit (Part I of the trial). There were 21 (58.3%) males, with average current age of 38.1
(SD 9.0) years and average time since diagnosis of 31.1 (SD 7.6) years. There were 35 (97%)
White and 1 (3%) Black participants. 19 (53%) received cranial RT treatment.
Feasibility
Three participants did not complete the Part I campus visit and thus were considered nonparticipants. Two other participants withdrew due to unrelated health problems. This resulted in
a total of 31 eligible participants for Part II. Feasibility in Part II was evaluated using Simon’s
Two-Stage design. Among a total of 31 eligible participants, two survivors enrolled but did not
initiate the remote session due to work schedule or time pressure, another survivor passively
withdrew from Part II session. This left a total of 28 participants in the remote session, with a
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participant rate of 90%, (exact 95% Confidence Interval, CI 74-98%). Of the 28 participants that
started, 25 completed Part II (89%, 95% CI 78-98%), 25/31 eligible completed (81%, 95% CI
63-93%), and 22/25 (88%; CI 69% - 97%) completed all 10 sessions. Among the 25 participants
who completed stimulation, 10 participants finished all 10 of the cognitive training sessions and
15 finished at least six of the sessions.
When comparing the eligible survivors who participated (n=28) vs. who did not
participate (n=3), or eligible who completed the remote-session (n=25) with those who did not
complete (n=6), there were no significant differences with respect to survivor characteristic such
as sex, age at diagnosis, follow-up in years or CRT treatment (Table 13). This suggested that the
trial as proposed in Part II was “feasible”.

Table 13 Survivor Demographics and Treatment Characteristics
Survivor
Characteristics
Gender
Race
Crinial RT
Age at diagnosis (yrs)
Time since diagnosis
(yrs)
Current Age (yrs)

Group
Female
Male
Black
White
No
Yes
Mean (SD)
Mean (SD)

Participants in
Part I (n=33)
13 (39.4)
20 (60.6)
1 ( 3.0)
32 (97.0)
15 (45.5)
18 (54.5)
7.4(4.4)
30.6(7.4)

Mean (SD)

37.9(9.1)

Participants in
Part II (n=28)
11 (39.3)
17 (60.7)
0 (0)
28 ( 100)
11 (39.3)
17 (60.7)
7.3(4.6)
31.5(7.5)
38.8(9.6)

Complete Part II
(n=25)
10 (40.0)
15 (60.0)
0 (0)
25 ( 100)
10 (40.0)
15 (60.0)
7.4(4.6)
31.5(7.9)
38.9(9.9)

AE profile in Part I
In Part I, 17 out of 33 (52%) participants reported a total of 26 related or possibly related
adverse events, with 12 events reported following active tDCS stimulation and 14 reported
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following sham stimulation. The most common reported symptom was itching/tingling (11
participants reported a total of 16 episodes; eight episodes were reported from tDCS and eight
from sham stimulation). The intensity (severities) of AE were reported as 13 (50%) “Not-severe
(No side effect)”, 7 (27%) “Trivial”, 6 (23%) “Mild”. In report of tolerability for worst symptom
the survivors reported all 26 side effects were tolerable. There was no grade 3 or higher CTCAE
toxicities either in Part I or Part II of the study thus rendering the trial “acceptable.” No
differences were observed between active stimulation and sham stimulation in terms of
symptoms and severity (Table 14).
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Table 14 Adverse Event during Clinic Visit (Part I)

Adverse
Event

Class

N

Overall
Episode
N(%)
6 (23.1)
13 (50.0)
7 (26.9)
1 ( 3.8)
4 (15.4)
1 ( 3.8)
16 (61.5)

tDCS Stimulation
Episode
N
N (%)
2
2 (16.7)
6
6 (50.0)
4
4 (33.3)
0
0 (0)
2
2 (16.7)
0
0 (0)
8
8 (66.7)

Sham Stimulation
Episode
N
N (%)
4
4 (28.57)
7
7 (50.00)
3
3 (21.43)
1
1 ( 7.14)
2
2 (14.29)
1
1 ( 7.14)
8
8 (57.14)

Mild
6
Not Severe
11
Trivial
5
Decreased Energy
1
Headache
4
Increased Perspiration 1
Symptom
Itching/ Tingling
11
Vivid dreams/
4
4 (15.4)
1
2 ( 16.7)
0
0 (0)
Nightmares
†
Chi-Square test on the comparison of frequency of episodes between tDCS and Sham Stimulation.
Severity

72

p-value

0.69

0.76

AE profile in Part II
Over the 248 remote sessions conducted among 28 participants, a total of 110 adverse
events were reported from 21 participants. The most commonly observed events were “Vivid
dreams/Nightmares” (n=35, 32%), “Headaches” (n=22, 20%) and “Itching” (n=21, 19%; Table
14). In report of tolerability for worse symptom the survivors reported, three participants
reported 8 (7%) episodes with distressing and 93% were tolerable. The severities of AE were
reported as 49 (45%) “Not-severe”, 18 (17%) “Trivial”, 23 (21%) “Mild”, 12 (11%) “Moderate”,
2 (2%) “Marked” and 5 (5%) “Severe” (Table 15). There were two participants who completed
only 4/10 session, one cited too many side effects and the other cited recurrent headaches as the
reason for not completing the study, but among all the symptoms reported none were SAE with
grade higher than 1 as per CTCAE.
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Table 15 Adverse Event during Remote Session (Part II)
Symptom
Anxiety
Difficulty Sleeping
Dizziness/Drowsiness during the day
General Malaise/ fatigue/ restlessness
Headache
Increased perspiration
Itching
Poor concentration
Poor coordination
Rash
Ringing in ears
Sleeping to much
Soreness at one stimulation site
Tingling
Tremors
Vivid dreams/ Nightmares
dry skin
Total

N of
subjects
1
4
3
2
11
1
6
1
1
2
4
1
1
1
1
9
2

N of
Episodes
1
5
3
2
22
1
21
2
1
3
5
2
2
1
2
35
2
110

19
8
8
7
1
2

49
18
23
12
2
5
109

Severity
Not Severe
Trivial
Mild
Moderate
Marked
Severe
Total

Rate Worst Symptom (Tolerable/ Distressing)
3
8
21
101
109
†
Missing report on severity/tolerability

Distressing
Tolerable
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% (Episodes)
0.9
4.6
2.7
1.8
20.0
0.9
19.1
1.8
0.9
2.7
4.6
1.8
1.8
0.9
1.8
31.8
1.8
100

45.0
16.5
21.1
11.0
1.8
4.6
100.0

7.3
92.7
100

Efficacy:
Acute tDCS effect during clinic visit (Part I)
There were no significant differences between tDCS active stimulation and sham
stimulation for the changes in raw score of Gray Oral Reading Test (GORT-4), Woodcock
Johnson Understanding Directions, or evaluation on EF using NIH Toolbox (Table 16).
However, we did observe significant worsening in GORT (change in difference Mean= -1.1,
SD=1.5, p=0.02) and significant improvement in List sorting WM (change in difference Mean=
1.2, SD=2.0, p=0.003, Table 15) from Day 1 to Day 2. The reason for the decrease in score of
the GORT could be that these tests involve reading stories and answering questions for both days
and participants may feel less motivated when doing the test on Day 2. However, NIH tool box
are computerized test which include more dynamic pictures and moving targets on screen, and
the improvement on List sorting WM may indicate practice effect.
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Table 16 Effect of tDCS vs Sham Stimulation and Day 2 vs Day 1 Stimulation on Executive
Functions at Clinic Visit
Compare tDCS to Sham Stimulation
With
Stimulation
n
Mean (SD)
Executive Function
Reading
31
7.0 (1.8)
comprehension
Listening
31
17.5 ( 2.5)
comprehension
NIH Toolbox
Cognitive
28
28.9 ( 1.7)
Flexibility
inhibitory Control
30
20.0 ( 0.0)
Attention
Working Memory
30
16.8 ( 2.9)

With Sham
Mean (SD)
6.9 ( 2.1)

Difference
(Stimulation - Sham)
Mean (SD)
-0.2 ( 1.9)

p-value
0.64

17.4 ( 2.4)

-0.2 ( 2.0)

0.23

29.0 ( 1.3)

-0.1 ( 1.5)

0.81

19.9 ( 0.4)

0.1 ( 0.4)

0.18

16.9 ( 3.2)

-0.0 ( 2.4)

0.94

Difference
(Day2-Day1)
Mean (SD)
-1.1 ( 1.5)

p-value
0.023

Compare Day to Day2 Outcomes
Day1
Day2

n
Mean (SD)
Mean (SD)
Executive Function
Reading
31
7.5 ( 1.6)
6.4 ( 2.1)
comprehension
Listening
31
17.5 ( 2.5)
17.5 ( 2.4)
0.0 ( 2.0)
comprehension
NIH Toolbox
Cognitive
28
29.0 ( 1.6)
29.0 ( 1.5)
0.0 ( 1.5)
Flexibility
inhibitory Control
30
19.9 ( 0.4)
20.0 ( 0.2)
0.0 ( 0.4)
Attention
Working Memory
30
16.2 ( 2.8)
17.5 ( 3.2)
1.2 ( 2.0)
†
One sample t-test on the difference;
Note: Sample sizes are different depend on number of missing observations.

0.48

0.83
1
0.003

Efficacy of tDCS and cognitive training during Remote Sessions (Part II)

We observed marginal significant improvements in Working Memory (0.36 SD, p=0.07),
Task Efficiency (0.42 SD, p=0.049), and Emotional Regulation (0.57 SD, p=0.016) after 5 weeks
of remote sessions of combined tDCS stimulation and cognitive training (Table 17).
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Table 17 Effect of remote tDCS stimulation on Executive Functions over remote session

n

Pre- Remote Session

Post- Remote
Session

Mean (SD)

Mean (SD)

Neurocognitive Function
Memory
Short-Term Span
23
5.7 ( 1.0)
Executive Function
Working Memory
23
3.7 ( 1.0)
Verbal Fluency
23
33.1 (11.0)
Cognitive Flexibility 22
53.1 (38.9)
Attention
Focused Attention
23
9.4 ( 2.6)
CCSS Neurocognitive Questionnaire (CCSS-NCQ)
23
17.5 ( 3.3)
Task Efficiency
Memory
23
8.1 ( 2.4)
Organization
23
6.1 ( 1.7)
Emotional
23
5.9 ( 2.6)
Regulation
†

Difference (Post - Pre)
Effect Size
Mean (SD)
(Cohen’s d)

pvalue†

5.7 ( 0.9)

0.0 ( 0.9)

0

1

4.2 ( 1.0)
34.7 (12.0)
47.2 (24.0)

0.4 ( 1.1)
1.5 ( 5.3)
-6.1 (38.6)

0.36
0.28
0.16

0.067
0.18
0.47

10.0 ( 6.7)

0.6 ( 6.2)

0.1

0.64

16.2 ( 4.0)
8.3 ( 2.0)
5.7 ( 1.6)

-1.3 ( 3.1)
0.2 ( 1.9)
-0.3 ( 1.2)

0.42
0.11
0.25

0.049
0.66
0.19

4.7 ( 1.6)

-1.2 ( 2.1)

0.57

0.016

One sample t-test on the difference; Note: Sample sizes are different depend on number of missing observations.
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Based on the observed effect size, 5% type I error rate and 80% of power, we would require
40 participants to complete the remote session prior to reaching significance. The GLM analysis
conducted to test the association of demographic, treatment factors and pre- remote session
measurement on improvement in Executive Function outcomes suggested that participants who
started with worse working memory demonstrated a larger improvement after the remote
sessions. Similarly, worse Task Efficiency or Emotional Regulation skills at pre- remote session
were associated with better improvement (more reduced in measurement) after remote session.
Cranial RT was associated with smaller improvement in Emotional Regulation skills (Table 18).
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Table 18 Multivariable analysis on Executive Function changes during remote session
Change in Short-Term Span: Model fit p=0.041, R Square=0.47
Parameter
Short-Term Span pre-remote
age at diagnosis (yrs)
gender Female vs. male
Cranial RT
Time since diagnosis (yrs)

Estimate
-0.753
0.066
0.289
-0.243
-0.043

SE
0.204
0.047
0.449
0.452
0.028

p-value
0.0018
0.18
0.53
0.60
0.15

Change in Task Efficiency Raw: Model fit p=0.77, R Square=0.23
Parameter
Estimate
SE
p-value
Task Efficiency pre-remote

-0.461

0.240

0.07

age at diagnosis (yrs)
gender Female vs. male
Cranial RT
Time since diagnosis (yrs)

0.103
-1.891
1.451
-0.119

0.163
1.635
1.574
0.098

0.54
0.26
0.37
0.24

Change in Emotional Regulation Raw: Model fit p=0.0003, R-square
=0.72
Parameter
Estimate
SE
p-value
Emotional Regulation pre-0.665
0.111
<.0001
remote
age at diagnosis (yrs)
-0.022
0.068
0.75
gender Female vs. male
0.362
0.631
0.57
Cranial RT
1.383
0.650
0.048
Time since diagnosis (yrs)
-0.017
0.041
0.69
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Discussion
In the current study, we conducted a Phase II trial of home-based intervention using
tDCS and cognitive stimulation for long-term adult survivors of childhood ALL who
experienced executive dysfunction. We concluded that the intervention was feasible, welltolerated, and suggested moderate clinically meaningful improvement in executive function. The
current study had 90% participant rate and 89% completion rate during the 5-week, specifically
79% completed all 10 sessions. These findings suggest that the intervention may apply to a larger
study over extended period of time.
Feasibility
It has been shown that the effect of tDCS is cumulative and that multiple sessions are
needed, but traveling to clinics multiple times for tDCS intervention is difficult. For this reason,
standard protocols for remotely-supervised tDCS for clinical trials have been developed for
Attention Deficit Hyperactivity Disorder, Depression, Multiple Sclerosis, and Palliative Care
groups.131 We conducted a similar clinical trial with a completion rate of 89% among long-term
cancer survivors. The results of our study are consistent with Kasschau et al. (2015)132, who
reported that 19/20 (95%) participants with Multiple Sclerosis completed ≥8 (out of 10) sessions
of remotely supervised tDCS intervention. Similarly, Ownby et al. (2016)133 reported a
completion rate of 79% (11/14) in individuals with HIV and neurocognitive difficulties who
were treated at the stimulation dose of 1.5mA. The feasibility and tolerability of tDCS was also
demonstrated by Andrade et al. (2014)134 in 14 children in the age range of 5 to 12 years.
The most common adverse events from remote tDCS stimulation were “Vivid dreams/
Nightmares”, “Headache” and “Itching” during stimulation. The most common adverse events
noted from Kasschau et al. (2015)132, were Skin tingling (72%), Skin itching (31%) and Skin
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burning (27%). However, the dose of stimulation was also slightly higher at 1.5mA compared to
1mA in our cohort. The most common adverse events observed by Andrade et al. (2014)134 were
tingling (28.6%), itching (28.6%) and acute mood change (42.9%). From these data, one can
infer that the administration of tDCS intervention remotely at dose levels in the range of 1mA2.0mA should be relatively safe with minor but manageable adverse events.
In Part I of the trial, similar rates of AEs were reported during Sham as well as active
stimulations which would once again suggest that treatment with tDCS does not pose any
additional or significant risks over what would be expected with sham treatment. In a metaanalysis, the participant drop-out rate between sham and tDCS groups in randomized studies
were similar but an evaluation of the AEs between the two groups was not feasible due to
heterogeneity of studies32.
Potential Efficacy for single session and remote session
Many studies have been conducted on the efficacy of single session tDCS stimulations. The
idea of including sham treatment in the design of the studies would be to essentially tease out
beneficial effects from practice effects. However, the data on the efficacy of tDCS as a treatment
modality for improving various cognitive performances, including language, memory and
executive function has been inconclusive due to the heterogeneity of participants. In a systematic
review on randomized trials using single session DLPFC anodal tDCS with sham stimulation as
control, healthy participants (N=102) respond significantly faster after anodal tDCS compared to
sham stimulation on cognitive task, with Cohen's d of −0.107 (p < 0.01).112 However, t-DCS was
not associated with significant improvement in accuracy among healthy participants, while a
significant influence of current density and density charge on accuracy was identified.112 Among
neuropsychiatric patients, only accuracy (Cohen’s d of 0.22, p<0.05) but not reaction time
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improved on cognitive tasks.112 Horvath et al. (2015)135 have made strong claims about the null
effects of tDCS on cognition from single-session. However, this was challenged by Price and
Hamilton (2015) 136, who based on the meta-analysis of 53 studies suggested that this lack of
efficacy of one session of tDCS on cognitive function was essentially attributable to poor quality
of the studies, including selection criteria, choice of behavioral measures used to assess
improvements, poor statistical approaches and sample sizes.
Assessment of the efficacy from remote tDCS intervention in conjunction with cognitive
training suggested potential clinically important improvements in working memory, Task
Efficiency and Emotional Regulation at the end of remote sessions. We found that survivors with
worse execution function at pre-remote session showed a larger improvement after 5-weeks of
remote sessions, which suggested that identification of potential beneficial population could be
critical for such trials. Philipp Ruf et al (2017) also showed that effects on improvement of
working memory from tDCS are dependent on the pre-training performance, that participants
with relatively low working memory ability benefit the most. 137 It has been suggested in several
studies that the effectiveness of the tDCS intervention can improve with increased number of
sessions as the effects may be cumulative131. A meta-analysis138 that evaluated several studies for
the efficacy of tDCS on cognitive function in various neurological disorders that include
Parkinson’s disease, Alzheimer ’s disease, Hemi-spatial Neglect and Aphasia concluded that
more studies were needed to gain better understanding of the efficacy of tDCS as a new tool for
rehabilitation of cognitive disorder. Similarly, another meta-analysis (Yokoi et al. 2015)139
concluded that the efficacy of tDCS for cognitive enhancements and/or treatment of
Schizophrenia are less consistent. It is worth noting that many of the studies evaluated in these
meta-analyses involved 3-30 sessions over 2-6 weeks with 3-5 sessions per week and the dose of
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the current intensity varied in the range from1.0 – 2.0 mA. These factors, dose of the current
stimulation, the duration of the tDCS intervention and the length of the intervention can certainly
affect the efficacy of tDCS on cognitive function. There has also been a concerted effort
(Santarnecchi 2015)110 to combine the tDCS intervention with other interventions such as
cognitive training, physical activity or pharmacologic agents and assessing synergistic effects of
two or more interventions together. Significant hurdles are imposed on patients, in terms of time
and cost, if they are required to receive the tDCS intervention in clinical setting. It would be far
more convenient and likely more efficacious, because of possibly better adherence, if the
participants could learn to self-administer tDCS intervention using mobile tDCS devices
remotely with or without the supervision of a trained clinician.
Limitations
Several limitations should be taken into account while interpreting the results from this
study. It is clear that we utilized sham session only in Part I of the trial and not in Part II so one
cannot rule out the fact that the improvements seen in executive function measures could be due
to practice effects. Since this was essentially a feasibility study, we were not powered to evaluate
the improvements in executive function measures. In the remote sessions, the tDCS intervention
was combined with Lumosity cognitive training and thus it would not be possible to separate the
effect size of tDCS stimulation from cognitive training. However, this was a pilot study, with the
goal to test the combined/synergic effects from the two approaches. In a future study design with
a larger group, this combined effect could be assessed with three arms tDCS stimulation alone,
Lumosity alone, and both. In this study, the researchers used Skype to ensure that the participants
were using the tDCS mobile correctly and also providing specific codes for each session so that
they would be delivering the right dose and not be able use the device more than stipulated
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session in between. This is a good solution for studies of shorter duration but could be a
limitation for larger studies. It would be desirable to have studies where the participants are able
to self-administer the intervention at the specified dose levels at specified time intervals without
remote monitoring. Finally, we cannot conclude how long the improvement on executive
function during the 5-week session could be retained, a longer follow-up such as evaluation after
six months of the remote session would provide information on this concern.
Based on our findings in the current study, we would propose a randomized trial on
comparing tDCS & Cognitive training vs. placebo on working memory, to achieve 0.5 SD mean
improvement in treatment group and no difference in placebo group, assume the correlation
coefficient of work memory outcomes between baseline and follow-up is 0.5 with equal variance
between treatment and placebo group, Type I error rate of 0.05, 80% power and attrition rate of
20%, we would need to enroll a total of 160 (80 per group) subjects for the trial (80 per group).
We would propose another randomized train on emotional regulation and achieve 0.7SD mean
difference between treatment and placebo group, with all other parameters keeping the same, we
would need enroll a total of 85 subjects (42/43 per group).
In current study, we found that remote tDCS stimulation combined with cognitive
training is feasible with some evidence of efficacy for long-term cancer survivors who have
demonstrated cognitive impairment. The findings from this study are promising and lay the
ground work for undertaking larger, possibly randomized, trials that investigate the effectiveness
of tDCS at various dose levels over a longer time period, possibly six months or longer, and
include 5-10 sessions per week. In addition, it will be equally important to evaluate the sustained
effects of the intervention over extended period of time, maybe after six months after the tDCS
intervention, to assess how long the effects of the intervention would be maintained.
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Chapter 5
CONCLUSION
Contemporary chemotherapy results in 5-year survival rate of greater than 90% for
children with acute lymphoblastic leukemia (ALL) without the use of cranial radiation therapy
(CRT).13 However survivors of long-term childhood ALL still present with a higher prevalence
of neurocognitive function problems, specifically executive function deficits15, and behavioral
and emotional problems63,65,140 compared to the general population. This dissertation presents
two epidemiologic studies on these issues, as well as a Phase II clinical trial to evaluate the
feasibility and potential efficacy of improving executive function deficits among long-term
childhood ALL survivors.
In Chapter 1, we reported results of a study including 158 survivors of childhood ALL
survivors (52% females, 77% White, mean age at diagnosis 6.6 years) previously treated at St.
Jude Children’s Research Hospital on the Total Therapy XV protocol.13 We evaluated the
association between sustained attention and parent-rated behavioral inattention at the end of
chemotherapy, and neurocognitive outcomes (executive function, sustained attention and
processing speed) at long-term follow-up. At 120 weeks post completion of consolidation,
participants demonstrated lower skills and a higher frequency of impairment in sustained
attention compared to expected 10% prevalence) on computerized testing (Conners' Continuous
Performance Test CPT II).50 Parents also reported a higher prevalence of inattention (20%) on
standardized ratings of child behavior (Conners' Parent Rating Scale CPRS)51 compared to
population expectations (10%). Higher methotrexate AUC and greater number of intrathecal
injections were associated with attention problems at the end of chemotherapy. At long-term
follow-up, survivors demonstrated lower executive functions with higher impairment on
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cognitively flexibility (24% impaired), fluency (21% impaired), and organization (54%
impaired) tested by Delis-Kaplan Executive Function System (DKEFS);52 higher frequency of
impairment for sustained attention on CPT50 (15%); and lower processing speed (15-43%
impaired) from Wechsler Intelligence Scale for Children (WISC-IV).53 Interestingly, survivors
improved on measures of sustained attention by an average of one to two standard deviations
from end of therapy to long-term follow-up. We conducted a mediation analysis and results
showed that the end of therapy sustained attention problems and behavior inattention did not
mediate the chemotherapy effect on the executive function deficits at long-term follow-up. The
direct effect of chemotherapy exposure predicted outcomes at both time points. These findings
suggest that for those patients who are going to receive higher concentrations of intravenous
methotrexate and more intrathecal treatments, the risk for neurocognitive deficits will be higher
than those who will receive lower dose of chemotherapy treatments, thus early therapeutic
interventions targeting on neurocognitive function during or shortly after active chemotherapy
treatment should be taken into consideration.
In Chapter 2, for the same group of childhood ALL survivors, at long-term follow-up, we
examined the prevalence and pattern of parent-reported and self-reported child behavioral and
emotional symptoms, as well as the prevalence of survivors’ mental health disorders, diagnosed
through structured diagnostic interviews with parents. We also evaluated the impact of parent
self-reported emotional distress and post-traumatic stress symptoms (PTSS) on the report of
child behavioral and emotional symptoms and mental health disorders. Survivor self-report
(Conners’ Rating Scale, 3rd edition71) demonstrated a larger proportion of symptoms of
inattention, hyperactivity/impulsivity, learning problems, ADHD hyperactive-impulsive type,
ADHD inattentive type, and Oppositional Defiant Disorder, with impairment proportions ranging
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from 20-29%, compared to expected 10%. Parent report of child behavioral and emotional
symptoms (Behavior Assessment System for Children [BASC-2]72) demonstrated statistically
significantly higher rates in the areas of depression, attention problems and problems with
activities of daily living (range 17-26%). The diagnostic Interview for Children and Adolescents
(DICA-IV)73, that systematically evaluated mental health disorders based on DSM-IV diagnostic
criteria for children, demonstrated that survivors have higher rates for Generalized Anxiety
Disorder (GAD, 3.2 vs. 1.1%), Obsessive-Compulsive Disorder (OCD, 10.3 vs. 3%) and
Oppositional Defiant Disorder (ODD, 16.0 vs. 8.3%) compared to rates in the general population
of adolescents. Agreement between parents and child was demonstrated between diagnosis of
Oppositional Defiant Disorder based on structured diagnostic interview, and survivors’ report of
symptoms. However, the anxiety disorders reported by parents from structured interview were
not associated with survivors’ self-report of anxiety symptoms. Rather, they were significantly
associated with parent self-reported emotional distress and PTSS, which suggested that
emotional distress in parents should also be taken into consideration for preventative intervention
targeting behavioral outcomes in survivors of childhood ALL.
Attention and executive functions such as inhibitory control, working memory, cognitive
flexibility, organization (problem solving) skills and emotional regulation controls are important
for children to comply with parental demands. Deficits in these skills may contribute to negative
interaction with parents and lead to a pattern of perceived defiant behaviors.77 Long-term
childhood ALL survivors treated with chemotherapy only show higher frequency of impairment
in executive function compared to the general population7 and impaired executive dysfunctions
were associated with emotional/behavioral problems,80 which may explain the high prevalence of
Oppositional Defiant Disorder in this population. Therefore, interventions targeted Oppositional
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Defiant Disorder may need to be modified to take into account the neurocognitive functioning
problems of survivors.
From the above two studies we may conclude that long-term survivors of childhood ALL
may need proactive intervention on both executive function and oppositional behaviors. We
designed and conducted a Phase II study combining Transcranial Direct Current Stimulation
(tDCS) and cognitive training targeted improving executive function among long-term childhood
ALL survivors. This is the first study of application tDCS to long-term childhood cancer
survivors (ClinicalTrials.gov ID NCT02336282). TDCS has been widely used to improve
cognitive tasks among healthy volunteers and neuropsychiatric patients and has been proven to
be a very safe approach.108,110,112,113,115,141 In this trial, we first evaluated the short-term effect of
tDCS compared to sham stimulation on performance on executive function during a two-day
period clinic visit by using a cross-over design. We then conducted a self-administering tDCS
trial over 5 weeks (with a total of 10 sessions) using a mobile tDCS device paired with cognitive
stimulation. The purpose of the study was to evaluate the feasibility and potential efficacy of
tDCS. Adverse events were closely monitored in both the clinic visits and remote sessions of the
trial and were considered as part of feasibility of the trial.
All participants enrolled in this trial were adult survivors of ALL who presented with
executive function deficits. Participants were evaluated before and after stimulation at both days
of clinic visit. For the remote stimulation sessions, neurocognitive testings129,122,130 were
conducted via video conference prior to the first stimulation session and following the last
stimulation session. We observed a 90% of participant rate (exact 95% CI 74-98%) and 89%
(95% CI 78-98%) of completion rate among participants for the remote stimulation session.
Participants reported no grade 2 or higher CTCAE toxicities and reported Adverse Events were
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“acceptable” either in clinic visit or during remote stimulations session of the study. Given this
participant rates and low AEs, we concluded the trial was “feasible”. We did not find an acute
tDCS effect during clinic visit but did observed marginal significant improvements in executive
functions of working memory, task efficiency and emotional regulation after 5 weeks of remote
sessions of combined tDCS stimulation and cognitive training.
The finding from this study is promising and may lay the foundation for future larger
randomized trials on the effectiveness of tDCS over extended period of time. However, since this
is a Phase II trial on feasibility of combing tDCS and cognitive training on the improvement of
executive functions for long-term childhood ALL survivors, we were not able to assess the
efficacy of tDCS apart from cognitive training, neither could we determine if the observed
improvement in executive function were from practice effect since we did not have sham
stimulation group. Future study design may include tDCS, sham and cognitive training treatment
arms as well as the combination of tDCS with cognitive training arm for a longer time period of
remote session, and evaluation on the improvement of executive function for a longer follow-up
(e.g. six months) may be conducted on examining the sustained intervention effect.
In conclusion, most children diagnosed with ALL progress through treatment into longterm survivorships and eventually into adulthood. Our research demonstrates attention problems
at the end of therapy, neurocognitive problems, and child and parent emotional problems during
long-term follow-up, and executive dysfunction and emotional regulation problems during
adulthood. Chemotherapy is associated with the attention problems and neurocognitive
impairment, but we cannot use the end of therapy attention problems as a reliable predictor of
future deficits. Parent emotional distress is also associated with child mental health.
Neurocognitive problems may also impact child mental health and both may impact adult
89

cognitive and emotional regulation problems. TDCS may be effective in treating these problems
during adulthood, though we need a larger RCT to confirm our pilot work. However, we also
need to explore early prevent and intervention trials to target the neurocognitive problems, child
mental health problems and parent emotional distress. These are areas in need of further study
(Figure 9).

Figure 9 Overall conclusion
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